ouabain rat induced designed models arrhythmia
aconitine using designed models arrhythmia
ouabain aconitine induced rat arrhythmic
aconitine induced rat arrhythmic
CBDCA use cause damage peripheral
CBDCA use cause damage nervous
CBDCA use cause damage system
CBDCA use cause damage
CBDCA dose neurotoxicity peripheral
CBDCA dose neurotoxicity
doxorubicin cardiomyopathy
doxorubicin produced cardiomyopathy
doxorubicin produced cardiomyopathy CM
doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease myocardial
doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease
DXR doxorubicin produced cardiomyopathy
DXR doxorubicin produced cardiomyopathy CM
DXR doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease myocardial
DXR doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease
Adriamycin doxorubicin produced cardiomyopathy
Adriamycin doxorubicin produced cardiomyopathy CM
Adriamycin doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease myocardial
Adriamycin doxorubicin produced cardiomyopathy provides opportunity analyze dose relationships development disease
DXR proportional damage CM
DXR proportional damage myocardial
DXR proportional damage
DXR dose insult degree proportional damage CM
DXR dose insult degree proportional damage myocardial
DXR dose insult degree proportional damage
propranolol toxicity associated syndrome Amnestic
propranolol toxicity associated syndrome
warfarin model hemorrhage associated hemorrhage intracerebral
warfarin model hemorrhage associated hemorrhage
Warfarin associated type hemorrhage intracerebral
Warfarin associated type hemorrhage
Warfarin associated type hemorrhage W ICH
Cocaine induced seizures
haloperidol induced catalepsy
haloperidol duration induced catalepsy
phenylephrine indicate instituted hypertension
dietary supplementation effect importantly contributes treated rats hypertensive
sodium supplementation effect importantly contributes treated rats hypertensive
chloride supplementation effect importantly contributes treated rats hypertensive
dietary supplementation effect hypertensive
sodium supplementation effect hypertensive
chloride supplementation effect hypertensive
dietary increase
dietary increase eliminated MAP in
dietary increase eliminated MAP
sodium increase
sodium increase eliminated MAP in
sodium increase eliminated MAP
chloride increase
chloride increase eliminated MAP in
chloride increase eliminated MAP
combined contraceptives women thromboembolism thromboembolism venous
combined contraceptives women thromboembolism thromboembolism
oral contraceptives women thromboembolism thromboembolism venous
oral contraceptives women thromboembolism thromboembolism
contraceptives women thromboembolism thromboembolism venous
contraceptives women thromboembolism thromboembolism
combined contraceptives women thromboembolism thromboembolism VTE
oral contraceptives women thromboembolism thromboembolism VTE
contraceptives women thromboembolism thromboembolism VTE
COCs thromboembolism venous
COCs thromboembolism
COCs thromboembolism VTE
COCs had while VTE
COCs women years 2 years COCs 1 women risk VTE
COCs 1 women risk VTE
COCs women VTE
Puromycin aminonucleoside administered induce proteinuria
aminonucleoside administered induce proteinuria
PAN aminonucleoside administered induce proteinuria
Haloperidol induced rigidity muscle
Haloperidol induced rigidity
haloperidol diminished rigidity muscle
haloperidol diminished rigidity
azidothymidine mice treatment produces myelodysplasia
AZT treatment produces myelodysplasia
AZT induced anemia macrocytic
AZT induced anemia
AZT therapy induced anemia macrocytic
AZT therapy induced anemia
AZT incorporation induced mentioned cells known seen syndrome myelodysplastic
AZT incorporation induced mentioned cells known seen syndrome
morphine cord changes 801 MK induced paraparesis spastic
morphine cord changes 801 MK induced paraparesis
morphine reduced paraparesis spastic
morphine reduced paraparesis
morphine induces paraparesis spastic
morphine induces paraparesis
ribavirin interferon therapy events one anemia Hemolytic
ribavirin interferon therapy events one anemia
interferon therapy events one anemia Hemolytic
interferon therapy events one anemia
ribavirin anemia hemolytic
ribavirin anemia
rifampicin administration subsequent Acute
rifampicin administration subsequent failure renal
rifampicin administration subsequent failure
dilevalol mechanism hepatitis
dilevalol mechanism reaction Hypersensitivity
dilevalol assess induced injury liver
dilevalol assess induced injury
dilevalol antigens containing serum assess induced injury liver
dilevalol antigens containing serum assess induced injury
dilevalol case antigens containing serum assess induced injury liver
dilevalol case antigens containing serum assess induced injury
dilevalol diagnosis woman year injury liver
dilevalol diagnosis woman year injury
dilevalol antigens prepared used injury liver
dilevalol antigens prepared used injury
dilevalol mechanism involvement suggesting prepared used injury liver
dilevalol mechanism involvement suggesting prepared used injury
cocaine Absence associated hemorrhage subarachnoid
cocaine Absence associated hemorrhage
cocaine patients angiograms obtained associated hemorrhage subarachnoid
cocaine patients angiograms obtained associated hemorrhage
cocaine patients angiograms obtained associated hemorrhage SAH
cocaine use underwent hemorrhage subarachnoid
cocaine use underwent hemorrhage
cocaine use underwent hemorrhage SAH
cocaine toxicology identified screened retrospectively SAH
cocaine use associated SAH
cocaine use associated SAH aneurysmal
5 undergoing assess incidence changes ischemic
FU infusion 5 undergoing assess incidence changes ischemic
5 infusion angina rare episodes Anginal
FU infusion angina rare episodes Anginal
5 infusion angina
FU infusion angina
5 02 0 13 0 + 0 incidence episodes ischemic
FU 0 13 0 + 0 incidence episodes ischemic
5 03 + 0 incidence episodes ischemic
FU infusion 0 incidence episodes ischemic
5 hour minutes + duration less P infusion 0 incidence episodes ischemic
FU v + minutes + duration less P infusion 0 incidence episodes ischemic
5 hour patient minutes + minutes + duration less P infusion 0 incidence episodes ischemic
FU P minutes + minutes + duration less P infusion 0 incidence episodes ischemic
5 infusion associated increase ischemia
- infusion associated increase ischemia
FU infusion associated increase ischemia
epinephrine overflow stimulus induced mediated rats hypertensive
Amphotericin B induced seizures
B induced seizures
amphotericin infusion patent report case episodes activity seizure
B infusion patent report case episodes activity seizure
amphotericin B infusion experienced stopped seizures
B infusion experienced stopped seizures
amphotercin administration occurred persisted seizures
B administration occurred persisted seizures
amphotericin B cause seizures
B cause seizures
Amphotericin B seems cause seizures
B seems cause seizures
amphotericin B associated seizures
B associated seizures
scopolamine amnesia
scopolamine ritanserin effect amnesia
scopolamine amnesia
penicillamine Immunopathology disease glomerular
penicillamine Immunopathology disease
D developed proteinuria
penicillamine D developed proteinuria
morphine trinitrate effect induced evaluated patients sphincter
morphine trinitrate effect induced evaluated patients sphincter dyskinesia of
morphine trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
morphine trinitrate effect induced evaluated patients sphincter dyskinesia
prostigmine morphine trinitrate effect induced evaluated patients sphincter
prostigmine morphine trinitrate effect induced evaluated patients sphincter dyskinesia of
prostigmine morphine trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
prostigmine morphine trinitrate effect induced evaluated patients sphincter dyskinesia
morphine provocation caused indicating spasm
Prostigmine RESULTS caused indicating spasm
morphine effect overcome able relevance treatment sphincter
morphine effect overcome able relevance treatment sphincter dyskinesia of
morphine effect overcome able relevance treatment sphincter dyskinesia Oddi
morphine effect overcome able relevance treatment sphincter dyskinesia
Ethambutol associated neuropathy optic
Ethambutol associated neuropathy
Ethambutol used treatment prevalent associated loss visual
Ethambutol used treatment prevalent associated loss
ethambutol patients PICTURE associated neuropathy optic
ethambutol patients PICTURE associated neuropathy
Ethambutol usage associated loss visual
Ethambutol usage associated loss
dobutamine stress spasm coronary
dobutamine stress spasm artery
dobutamine stress spasm
dobutamine induced ischemia due spasm coronary
dobutamine induced ischemia due spasm
dobutamine provoke patients angina coronary
dobutamine provoke patients angina spastic
dobutamine provoke patients angina
dobutamine provoke spasm coronary
dobutamine provoke spasm
propofol Assessment onset amnesia
Vasopressin hypotension
milrinone treatment Vasopressin hypotension
milrinone inhibitors use restricted cause vasodilation hypotension
vasopressin doses restored patients failure hypotension
milrinone treatment hypotension
milrinone effect inhibiting restored patients failure hypotension
amphetamine reflects rotation contralateral
amphetamine reflects rotation
amphetamine examined clarify nature rotation contralateral
amphetamine examined clarify nature rotation
amphetamine induced behavior rotational
amphetamine induced behavior
amphetamine administered days lesioning involvement cells rotation contralateral
amphetamine administered days lesioning involvement cells rotation
amphetamine dose volume recovery duration regardless tended rotation
amphetamine duration regardless tended rotation
amphetamine injections circled tended rotation
amphetamine has suggest pool contributing rotation contralateral
amphetamine has suggest pool contributing rotation
Clarithromycin induced tachycardia ventricular
Clarithromycin induced tachycardia
erythromycin profile established gastroenteritis
Phenobarbital dyskinesia
phenobarbital therapy starting soon dyskinesia
phenobarbital challenge recurred dyskinesia
pilocarpine latency indicated increased seizures
pilocarpine latency indicated increased seizures
acetaminophen hepatotoxicity
acetaminophen hepatitis
acetaminophen suffering suggesting involves injury liver
acetaminophen suffering suggesting involves injury
AAP acetaminophen hepatitis
AAP acetaminophen suffering suggesting involves injury liver
AAP acetaminophen suffering suggesting involves injury
AAP injury involves suggesting suffering acetaminophen hepatitis
AAP injury liver
AAP injury
AAP hepatitis
ethanol consumption influence evaluates investigates effects diet substrate acts hepatitis
AAP presence measured inhibited damage liver
AAP presence measured inhibited damage
ethanol caused exacerbation inhibited damage liver
ethanol caused exacerbation inhibited damage
ethanol inhibited damage liver
ethanol inhibited damage
AAP mice given observed reduction hepatitis
ethanol mice given observed reduction hepatitis
AAP hepatitis
ethanol exacerbation AAP hepatitis
acetaminophen preparations use see avoid damage hepatic
acetaminophen preparations use see avoid damage
haloperidol induced catalepsy
haloperidol induced reverse catalepsy
Cyclophosphamide induced cystitis
Cyclophosphamide used induce cystitis
CP Cyclophosphamide used induce cystitis
CP model induced model allowing understanding syndromes painful
CP model induced model allowing understanding syndromes
CP model induced model cystitis
adriamycin activity Detection induced cardiomyopathy
adriamycin induced cardiomyopathy
adriamycin model Using tested hypothesis appear exacerbated cardiomyopathy
adriamycin cardiomyopathy exacerbated appear hypothesis tested Using model adriamycin induced cardiomyopathy
adriamycin cardiomyopathy
adriamycin detection method indicates appearance presence impairment myocardial
adriamycin detection method indicates appearance presence impairment
adriamycin induced cardiomyopathy
methysergide woman ingestion secondary described case vasospasm
ergot history discussion includes caused ages role management headache migraine
ergot history discussion includes caused ages role management headache
ergot preparations continue play therapy migraine
bendrofluazide treatment impotence
bendrofluazide treatment association show occurred impotence
propranolol taking patients occurred show association treatment impotence
propranolol taking patients occurred impotence
propranolol taking phenomenon Raynaud
propranolol taking phenomenon Raynaud '
propranolol taking phenomenon s
propranolol taking phenomenon
bendrofluazide treatment associated men gout
bendrofluazide treatment associated men gout tolerance impaired
bendrofluazide treatment associated men gout tolerance glucose
bendrofluazide treatment associated men gout tolerance
propranolol taking phenomenon dyspnoea
steroid therapy term defect ventricular
steroid therapy term defect septal
steroid therapy term defect
steroid ventricular
steroid ventricular rupture septal
steroid ventricular rupture
steroid therapy rupture septal
steroid therapy rupture
Clarithromycin associated hallucinations visual
Clarithromycin associated hallucinations
clarithromycin antibiotic occurring hallucinations visual
clarithromycin antibiotic occurring hallucinations
warfarin discontinued available patients lesions LV
warfarin discontinued available patients lesions Cutaneous
warfarin discontinued available patients lesions
paracetamol survivors Long induced failure acute
paracetamol survivors Long induced failure liver
paracetamol survivors Long induced failure
paracetamol survivors prognosis BACKGROUND induced remains failure acute
paracetamol survivors prognosis BACKGROUND induced remains failure liver
paracetamol survivors prognosis BACKGROUND induced remains failure
paracetamol induced increases acute
paracetamol induced increases liver
paracetamol induced increases failure
paracetamol caused ratio acute
paracetamol caused ratio liver
paracetamol caused ratio failure
paracetamol caused higher age age died survivors failure acute
paracetamol caused higher age age died survivors failure liver
paracetamol caused higher age age died survivors failure
Paracetamol CONCLUSIONS affect failure acute
Paracetamol CONCLUSIONS affect failure liver
Paracetamol CONCLUSIONS affect failure
heparin treatment ancrod Failure thrombosis
heparin associated remain thrombosis
heparin used prophylaxis development thrombosis
heparin used defined success patients developed syndrome thrombosis
heparin require aggregation induced heparin used prophylaxis development thrombosis
heparin require aggregation induced heparin used defined success patients developed syndrome thrombosis
heparin patient present thrombosis
Chlorpropamide induced neuropathy optic
Chlorpropamide induced neuropathy
chlorpropamide treated diabetes had neuropathy toxic
chlorpropamide treated diabetes had neuropathy optic
chlorpropamide treated diabetes had neuropathy
Diabenese diabetes had neuropathy toxic
Diabenese diabetes had neuropathy optic
Diabenese diabetes had neuropathy
chlorpropamide therapy discontinuation resolved neuropathy toxic
chlorpropamide therapy discontinuation resolved neuropathy optic
chlorpropamide therapy discontinuation resolved neuropathy
succinylcholine myalgia Postoperative
succinylcholine myalgia
succinylcholine associated effect myalgia postoperative
succinylcholine associated effect myalgia
succinylcholine incidence determined myalgia
succinylcholine pretreated patients determined myalgia
succinylcholine origin evidence myalgia
succinylcholine effective Administration IMPLICATIONS induced myalgia postoperative
succinylcholine effective Administration IMPLICATIONS induced myalgia
succinylcholine severity incidence decreasing effective Administration IMPLICATIONS induced myalgia postoperative
succinylcholine severity incidence decreasing effective Administration IMPLICATIONS induced myalgia
succinylcholine prevent myalgia postoperative
succinylcholine prevent myalgia
estrogens treatment implicated development cancer endometrial
estrogens treatment implicated development cancer
estrogens women have risk carcinoma endometrial
estrogens women have risk carcinoma
pilocarpine model epilepsy temporal
pilocarpine model epilepsy lobe
pilocarpine model epilepsy
PILO model TLE
tranexamic Acid associated seizures
Acid associated seizures
TXA usage seizures
TXA doses received patients seizures
TXA high surgery use associated seizures
paracetamol overdose due ALF
paracetamol overdose due defect ALF
risperidone Treatment hyperprolactinemia
Risperidone associated hyperprolactinemia
risperidone treatment report induced hyperprolactinemia
risperidone children review hyperprolactinemia
risperidone treatment hyperprolactinemia
LiCl pre administered Tacrine induces seizures
LiCl pre administered Tacrine induces seizures damage hippocampal
LiCl pre administered Tacrine induces seizures damage
Tacrine induces seizures damage hippocampal
Tacrine induces seizures damage
Tacrine induces seizures
tacrine administration induced damage
tacrine administration induced damage cells of
tacrine administration induced damage cells neuronal
tacrine administration induced damage cells
tacrine solution treated tacrine administration induced damage
tacrine solution treated tacrine administration induced damage cells of
tacrine solution treated tacrine administration induced damage cells neuronal
tacrine solution treated tacrine administration induced damage cells
penicillin potassium induced focus epileptic
G potassium induced focus epileptic
potassium induced focus epileptic
diclofenac etoricoxib lower rate due AEs GI
diclofenac etoricoxib lower rate due AEs
etoricoxib higher incidence discontinuations hypertension
etoricoxib % 0 001 hypertension
etoricoxib higher incidence discontinuations related oedema
etoricoxib % 0 001 01 oedema
diclofenac Discontinuations AEs GI
diclofenac Discontinuations AEs
diclofenac Discontinuations AEs higher common discontinuations AEs GI
diclofenac Discontinuations AEs higher common discontinuations AEs
metformin use associated jaundice Cholestatic
metformin use associated jaundice
metformin hydrochloride developed jaundice cholestatic
metformin hydrochloride developed jaundice
hydrochloride developed jaundice cholestatic
hydrochloride developed jaundice
succinylcholine apnoea
succinylcholine hours apnoea
succinylcholine apnoea
Amiodarone agent effects pneumonitis
doxorubicin + daunorubicin Sensitivity investigated toxicity hematologic
doxorubicin + daunorubicin Sensitivity investigated toxicity
daunorubicin Sensitivity investigated toxicity hematologic
daunorubicin Sensitivity investigated toxicity
etoposide daunorubicin Sensitivity investigated toxicity hematologic
etoposide daunorubicin Sensitivity investigated toxicity
etoposide daunorubicin reduced loss myelosuppression weight
etoposide daunorubicin reduced loss
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression loss weight
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression loss
doxorubicin cytotoxicity myelosuppression dexrazoxane antagonized reduced loss myelosuppression weight
doxorubicin cytotoxicity myelosuppression dexrazoxane antagonized reduced loss
doxorubicin cytotoxicity myelosuppression loss weight
doxorubicin cytotoxicity myelosuppression loss
daunorubicin reduced loss myelosuppression weight
daunorubicin reduced loss
daunorubicin reduced antagonized dexrazoxane myelosuppression loss weight
daunorubicin reduced antagonized dexrazoxane myelosuppression loss
etoposide doses combining metastases patients trials ongoing aim improving toxicity hematologic
etoposide doses combining metastases patients trials ongoing aim improving toxicity
amiodarone secondary hypothyroidism
amiodarone CHF Patients suffer hypothyroidism
furosemide Tetany
furosemide Tetany rhabdomyolysis
ribavirin strategies anemia hemolytic
ribavirin strategies anemia
ribavirin anemia hemolytic
ribavirin anemia
ribavirin anemia RIHA
ribavirin dosage reduction standard care management RIHA
ribavirin dose incidence RIHA
DEN given reduced number size foci preneoplastic
DEN given reduced number size foci
bupropion hydrochloride increasing Effect seizures
hydrochloride increasing Effect seizures
bupropion relationship seizures
bupropion HCl mg kg dose convulsive
HCl mg kg dose convulsive
bupropion HCl mg induced convulsions
HCl mg induced convulsions
bupropion severity kg dose convulsive
bupropion severity kg mg induced convulsions
bupropion mg administration kg induced convulsions
HCl mg administration kg induced convulsions
bupropion mg administration associated odds convulsions
HCl mg administration associated odds convulsions
bupropion mg time increasing revealed group induced convulsions
HCl mg time increasing revealed group induced convulsions
bupropion mg time increasing revealed group induced kg administration associated odds convulsions
HCl mg time increasing revealed group induced kg administration associated odds convulsions
bupropion dose fixed convulsive
bupropion dose risk convulsions
androgen administration sleep Induction obstructive
androgen administration sleep
androgen administration sleep syndrome apnea
androgen administration sleep syndrome
androgens exogenous developed changes syndrome
androgens exogenous developed changes syndrome apnea of
androgens exogenous developed changes syndrome apnea obstructive
androgens exogenous developed changes syndrome apnea sleep
androgens exogenous developed changes syndrome apnea
androgen rechallenge produced symptoms apnea obstructive
androgen rechallenge produced symptoms apnea sleep
androgen rechallenge produced symptoms apnea
androgen therapy effect considered Development syndrome obstructive
androgen therapy effect considered Development syndrome sleep
androgen therapy effect considered Development syndrome apnea
androgen therapy effect considered Development syndrome
metoclopramide arrest Cardiac
metoclopramide arrest
metoclopramide arrest case injections metoclopramide causing episodes arrest cardiac
metoclopramide arrest case injections metoclopramide causing episodes arrest
metoclopramide injections case arrest Cardiac
metoclopramide injections case arrest
metoclopramide causing episodes arrest cardiac
metoclopramide causing episodes arrest
metoclopramide injection followed asystole
metoclopramide administration followed asystole
metoclopramide caused arrest cardiac
metoclopramide caused arrest
levodopa patients selected dyskinesias
clomipramine effects sexual
clomipramine effects side
clomipramine effects
folic acid activity induces SLE
acid activity induces SLE
folic acid SLE
acid SLE
folic acid dose barrier triggered disease drug lupus
acid dose barrier triggered disease drug lupus
folic acid dose barrier triggered cluster seizures
acid dose barrier triggered cluster seizures
epsilon induce myopathy
aminocaproic acid epsilon induce myopathy
acid epsilon induce myopathy
EACA epsilon induce myopathy
Valproate induced chorea encephalopathy
Valproate induced chorea
valproate therapy initiation have hyperglycinemia presentation encephalopathy
valproate therapy initiation have hyperglycinemia presentation encephalopathy chorea
nimesulide Tolerability urticaria angioedema
NSAID Tolerability urticaria angioedema
paracetamol nimesulide Tolerability urticaria angioedema
nimesulide angioedema
NSAID history number paracetamol nimesulide angioedema
paracetamol nimesulide angioedema
nimesulide procedure applied patients history angioedema
NSAID angioedema
paracetamol nimesulide procedure applied patients history angioedema
NSAID history subjects % induced angioedema
NSAID history subjects % induced angioedema angioedema
nimesulide tolerability confirm patients experienced angioedema
NSAIDs caused angioedema
paracetamol nimesulide tolerability confirm patients experienced angioedema
NSAID history angioedema
carboplatin chemotherapy Acute
carboplatin chemotherapy Acute failure renal
carboplatin chemotherapy Acute failure
Carboplatin reported cause failure acute
Carboplatin reported cause failure renal
Carboplatin reported cause failure
amphotericin B prevention drug it hypokalemia
B prevention drug it hypokalemia
AmB treatment patients prevent hypokalemia
AmB treatment patients reducing prevent hypokalemia
enflurane resulted seizures
enflurane delineated foci ablated seizure
sulfasalazine associated Hepatotoxicity
sulfasalazine hepatotoxicity
sulfasalazine hepatotoxicity
sulfasalazine hepatotoxicity
sulfasalazine associated hepatotoxicity
fluphenazine enanthate induced parkinsonism
enanthate induced parkinsonism
benztropine treated had increase dyskinesia tardive
benztropine treated had increase dyskinesia
benztropine treated had condition anxiety depression
benztropine treated had condition anxiety
PTZ suppressed increased amplitude startle
PTZ suppressed increased suppressed startle
PTZ suppressed startle
yohimbine increased amplitude startle
yohimbine increased suppressed startle
yohimbine increased suppressed startle
mCPP suppressed increased amplitude startle
mCPP suppressed startle
mCPP suppressed increased suppressed startle
doxorubicin nephrosis
sodium powders ate reported case two nephrolithiasis
bicarbonate powders ate reported case two nephrolithiasis
calcium carbon amounts consumed patients reported case hypercalcaemia
carbon amounts consumed patients reported case hypercalcaemia
ate reported case hypercalcaemia
calcium carbon amounts consumed patients reported case two nephrolithiasis
carbon amounts consumed patients reported case two nephrolithiasis
ate reported case two nephrolithiasis
sodium powders ate reported case hypercalcaemia
bicarbonate powders ate reported case hypercalcaemia
terbutaline relationship induced hypokalemia
terbutaline concentrations spite antagonized hypokalemia
puromycin aminonucleoside hypoxia syndrome nephrotic
puromycin aminonucleoside hypoxia syndrome
aminonucleoside hypoxia syndrome nephrotic
aminonucleoside hypoxia syndrome
puromycin aminonucleoside hypoxia
aminonucleoside hypoxia
puromycin aminonucleoside hypoxia hypoxia
aminonucleoside hypoxia hypoxia
puromycin model weeks fold reaching increased Expression hypoxia
aminonucleoside model weeks fold reaching increased Expression hypoxia
norfloxacin ciprofloxacin rats showed behaviour anxious
norfloxacin ciprofloxacin rats showed behaviour
ciprofloxacin rats showed behaviour anxious
ciprofloxacin rats showed behaviour
warfarin juice haemopericardium haemorrhage gastrointestinal
warfarin juice haemopericardium haemorrhage
ketamine combinations induced potentiation Catalepsy
morphine ketamine combinations induced potentiation Catalepsy
ketamine induced analgesia catalepsy
morphine ketamine induced analgesia catalepsy
ketamine treatment Pre tolerance ketamine augmented response cataleptic
ketamine augmented response cataleptic
morphine tolerance cross produced treatment Pre tolerance ketamine augmented response cataleptic
morphine pretreatment induce produced treatment Pre tolerance ketamine augmented response cataleptic
morphine attributed tolerance ketamine augmented response cataleptic
ribavirin prodrug liver has potential maintain decreasing risk anemia hemolytic
ribavirin prodrug liver has potential maintain decreasing risk anemia
ribavirin efficacy maintain decreasing risk anemia hemolytic
ribavirin efficacy maintain decreasing risk anemia
vancomycin course receiving Acute
vancomycin course receiving Acute failure renal
vancomycin course receiving Acute failure
clomiphene citrate associated infarction Myocardial
clomiphene citrate associated infarction
citrate associated infarction Myocardial
citrate associated infarction
CC reported complication rare Thromboembolism
CC infarction myocardial
CC infarction
Mellaril appeared responsible cases tachycardia ventricular
Mellaril appeared responsible cases tachycardia
thioridazine Mellaril appeared responsible cases tachycardia ventricular
thioridazine Mellaril appeared responsible cases tachycardia
Aventyl produced block left
Aventyl produced block bundle
Aventyl produced block branch
Aventyl produced block
nortriptyline Aventyl produced block left
nortriptyline Aventyl produced block bundle
nortriptyline Aventyl produced block branch
nortriptyline Aventyl produced block
Elavil Aventyl produced block left
Elavil Aventyl produced block bundle
Elavil Aventyl produced block branch
Elavil Aventyl produced block
amitriptyline Elavil Aventyl produced block left
amitriptyline Elavil Aventyl produced block bundle
amitriptyline Elavil Aventyl produced block branch
amitriptyline Elavil Aventyl produced block
caffeine men hypertension
caffeine actions enhanced persons hypertensive
caffeine ingestion achieved levels hypertensive
caffeine were men hypertensive
caffeine were replicated protocols representative hypertensives
levomepromazine treatment induced Seizures
fluvoxamine treatment induced Seizures
levomepromazine induced seizures
fluvoxamine treatment levomepromazine induced seizures
tramadol intake Nightmares hallucinations
tramadol drugs hallucinations
doxorubicin heart derivative induced cardiomyopathy
doxorubicin courses received Animals demonstrated changes decrease cardiomyopathy
doxorubicin cardiomyopathy
terbutaline metoprolol antagonism hypokalemia
diphenylhydantoin toxicity manifestation hemiparesis
diphenylhydantoin overdose effects encountered those dysfunction cerebellar
diphenylhydantoin overdose effects encountered those dysfunction
DPH overdose effects encountered those dysfunction cerebellar
DPH overdose effects encountered those dysfunction
diphenylhydantoin overdose
DPH overdose
DPH overdose
DPH overdose due hemiparesis
metrizoate lower Frequencies fibrillation ventricular
metrizoate lower Frequencies fibrillation
ropivacaine levobupivacaine seizures
levobupivacaine seizures
ropivacaine doses smaller doses levobupivacaine produced dysrhythmias
levobupivacaine produced dysrhythmias
levobupivacaine produced dysrhythmias asystole
ropivacaine doses smaller doses levobupivacaine produced dysrhythmias asystole
levobupivacaine toxicity intermediate conclude appears arrest cardiac
levobupivacaine toxicity intermediate conclude appears arrest
levobupivacaine bupivacaine induced that treatment susceptible appears arrest cardiac
levobupivacaine bupivacaine induced that treatment susceptible appears arrest
ropivacaine that intermediate conclude appears arrest cardiac
ropivacaine that intermediate conclude appears arrest
ropivacaine rate administered intermediate conclude appears arrest cardiac
ropivacaine rate administered intermediate conclude appears arrest
gentamicin induced failure acute
gentamicin induced failure renal
gentamicin induced failure
pimecrolimus tacrolimus immunomodulators use regarded cause dermatitis
Heparin induced thrombocytopenia hemorrhage
Heparin induced thrombocytopenia
heparin patients Sixty induced reported thrombocytopenia
heparin receiving hemorrhage
heparin receiving hemorrhage events thromboembolic
carbachol produced mydriasis
carbachol produced mydriasis tremor
eserine carbachol produced mydriasis clonic
eserine carbachol produced convulsions tonic
eserine carbachol produced convulsions
eserine carbachol produced mydriasis
carbachol produced mydriasis clonic
carbachol produced convulsions tonic
carbachol produced convulsions
eserine carbachol produced mydriasis tremor
carbachol evoked convulsions changed hand mydriasis
carbachol evoked convulsions changed hand tremor
eserine carbachol evoked convulsions changed hand clonic
eserine carbachol evoked convulsions tonic
eserine carbachol evoked convulsions
eserine carbachol evoked convulsions changed hand mydriasis
carbachol evoked convulsions changed hand clonic
carbachol evoked convulsions tonic
carbachol evoked convulsions
eserine carbachol evoked convulsions changed hand tremor
carbachol caused convulsions phenomena mydriasis
carbachol caused convulsions phenomena mydriasis tremor
eserine carbachol caused convulsions phenomena mydriasis clonic
eserine carbachol caused convulsions tonic
eserine carbachol caused convulsions
eserine carbachol caused convulsions phenomena mydriasis
carbachol caused convulsions phenomena mydriasis clonic
carbachol caused convulsions tonic
carbachol caused convulsions
eserine carbachol caused convulsions phenomena mydriasis tremor
metoprolol treatment SR block shock heart
metoprolol treatment SR block
verapamil SR block shock heart
verapamil SR block
metoprolol use verapamil seventy eight year woman presented block heart
metoprolol use verapamil seventy eight year woman presented block
verapamil seventy eight year woman presented block heart
verapamil seventy eight year woman presented block
verapamil seventy eight year woman presented block hypotension
metoprolol use verapamil seventy eight year woman presented block hypotension
dextromethorphan abuse deterioration Cognitive
dextromethorphan abuse deterioration
DM use resulting deterioration cognitive
DM use resulting deterioration
FK A Nephrotoxicity
506 FK A Nephrotoxicity
cyclosporin A Nephrotoxicity
A Nephrotoxicity
FK CsA 506 effects nephrotoxic
506 effects nephrotoxic
CsA 506 effects nephrotoxic
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models Acute
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models experimental
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models damage of
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models damage renal
puromycin aminonucleoside butadiene 3 bromoethylamine administration produced models damage
aminonucleoside butadiene 3 bromoethylamine administration produced models Acute
aminonucleoside butadiene 3 bromoethylamine administration produced models experimental
aminonucleoside butadiene 3 bromoethylamine administration produced models
aminonucleoside butadiene 3 bromoethylamine administration produced models damage of
aminonucleoside butadiene 3 bromoethylamine administration produced models damage renal
aminonucleoside butadiene 3 bromoethylamine administration produced models damage
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models Acute
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models experimental
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models damage of
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models damage renal
PAN aminonucleoside butadiene 3 bromoethylamine administration produced models damage
2 butadiene 3 bromoethylamine administration produced models Acute
2 butadiene 3 bromoethylamine administration produced models experimental
2 butadiene 3 bromoethylamine administration produced models
2 butadiene 3 bromoethylamine administration produced models damage of
2 butadiene 3 bromoethylamine administration produced models damage renal
2 butadiene 3 bromoethylamine administration produced models damage
bromoethylamine administration produced models Acute
bromoethylamine administration produced models experimental
bromoethylamine administration produced models
bromoethylamine administration produced models damage of
bromoethylamine administration produced models damage renal
bromoethylamine administration produced models damage
BEA bromoethylamine administration produced models Acute
BEA bromoethylamine administration produced models experimental
BEA bromoethylamine administration produced models
BEA bromoethylamine administration produced models damage of
BEA bromoethylamine administration produced models damage renal
BEA bromoethylamine administration produced models damage
hexachloro bromoethylamine administration produced models Acute
hexachloro bromoethylamine administration produced models experimental
hexachloro bromoethylamine administration produced models
hexachloro bromoethylamine administration produced models damage of
hexachloro bromoethylamine administration produced models damage renal
hexachloro bromoethylamine administration produced models damage
1 3 bromoethylamine administration produced models Acute
1 3 bromoethylamine administration produced models experimental
1 3 bromoethylamine administration produced models
1 3 bromoethylamine administration produced models damage of
1 3 bromoethylamine administration produced models damage renal
1 3 bromoethylamine administration produced models damage
3 bromoethylamine administration produced models Acute
3 bromoethylamine administration produced models experimental
3 bromoethylamine administration produced models
3 bromoethylamine administration produced models damage of
3 bromoethylamine administration produced models damage renal
3 bromoethylamine administration produced models damage
butadiene 3 bromoethylamine administration produced models Acute
butadiene 3 bromoethylamine administration produced models experimental
butadiene 3 bromoethylamine administration produced models
butadiene 3 bromoethylamine administration produced models damage of
butadiene 3 bromoethylamine administration produced models damage renal
butadiene 3 bromoethylamine administration produced models damage
HCBD butadiene 3 bromoethylamine administration produced models Acute
HCBD butadiene 3 bromoethylamine administration produced models experimental
HCBD butadiene 3 bromoethylamine administration produced models
HCBD butadiene 3 bromoethylamine administration produced models damage of
HCBD butadiene 3 bromoethylamine administration produced models damage renal
HCBD butadiene 3 bromoethylamine administration produced models damage
droperidol administration associated Angioedema
droperidol dose administration minutes developed protrusion year man allergies angioedema
ethambutol induced neuropathy optic
ethambutol induced neuropathy
ethambutol map induced neuropathy optic
ethambutol map induced neuropathy
ethambutol complication neuropathy optic
ethambutol complication neuropathy
ethambutol history subjects METHODS long administered deficits visual
ethambutol history subjects METHODS long administered deficits
EMB ethambutol history subjects METHODS long administered deficits visual
EMB ethambutol history subjects METHODS long administered deficits
ethambutol history subjects METHODS induced neuropathy optic
ethambutol history subjects METHODS induced neuropathy
EMB ethambutol history subjects METHODS induced neuropathy optic
EMB ethambutol history subjects METHODS induced neuropathy
EMB history subjects was loss A recovery patient B deficits visual
EMB history subjects was loss A recovery patient B deficits
EMB history subjects was loss A recovery deficits visual
EMB history subjects was loss A recovery deficits
EMB history neuropathy optic
EMB history neuropathy
EMB patients results CONCLUSIONS induced show neuropathy optic
EMB patients results CONCLUSIONS induced show neuropathy
EMB induced neuropathy optic
EMB induced neuropathy
ethambutol dosing manage important terms management EMB induced neuropathy optic
ethambutol dosing manage important terms management EMB induced neuropathy
gentamicin failure acute
gentamicin failure renal
gentamicin failure
ifosfamide Treatment toxicity urothelial
ifosfamide Treatment toxicity
ifosfamide induced toxicity urothelial
ifosfamide induced toxicity
IF effect sodium sulphonate toxicity urothelial
IF effect sodium sulphonate toxicity
IF treatment tested effect sodium sulphonate toxicity urothelial
IF treatment tested effect sodium sulphonate toxicity
methylprednisolone cause was mention possibility myopathy
methylprednisolone offers protection recording recovers myopathy
methylprednisolone offers protection recording recovery myopathy
methylprednisolone cause myopathy
tamoxifen use associated tumor Granulosa
tamoxifen use associated tumor cell
tamoxifen use associated tumor
tamoxifen use associated tumor ovary of
tamoxifen use associated tumor ovary the
tamoxifen use associated tumor ovary
tamoxifen Patients CONCLUSION induced risk dysfunction liver
tamoxifen Patients CONCLUSION induced risk dysfunction
tamoxifen metabolism alterations tumors risk dysfunction liver
tamoxifen metabolism alterations tumors risk dysfunction
Li events DVP EPS
Li DVP different DVP EPS
haloperidol treated events related EPS
haloperidol treated experienced events related EPS
lithium treated patients 26 experienced treated events related EPS
lithium treated patients 26 experienced events related EPS
Lithium associated incidence tremor
Lithium associated contributed tremor
Lithium associated contributed rate tremor
lithium effect tremor contributed associated incidence tremor
lithium effect tremor
lithium effect tremor contributed rate tremor
lithium therapy receiving patients contributed associated incidence tremor
lithium therapy receiving patients contributed tremor
lithium therapy receiving patients contributed rate tremor
Haloperidol induced incidence akathisia syndrome extrapyramidal
Haloperidol induced incidence akathisia syndrome
Haloperidol induced incidence akathisia tremor
Haloperidol induced incidence akathisia
Dexamethasone induced hypertension ocular
Dexamethasone induced hypertension
dexamethasone treated thickened eyes hypertensive
dexamethasone treated thickened eyes
Dexamethasone treatment eyes led generation hypertension ocular
Dexamethasone treatment eyes led generation hypertension
dexamethasone % led generation hypertension ocular
dexamethasone % led generation hypertension
etomidate reduces myoclonus
etomidate induction compare incidence myoclonus
etomidate administration associated incidence myoclonus
etomidate induction reduced myoclonus
etomidate administration increased incidence myoclonus
adriamycin injection induced syndrome nephrotic
adriamycin injection induced syndrome
ADR adriamycin injection induced syndrome nephrotic
ADR adriamycin injection induced syndrome
paracetamol overdose survived failure fulminant
paracetamol overdose survived failure hepatic
paracetamol overdose survived failure
paracetamol overdose survived increased patients failure fulminant
paracetamol overdose survived increased patients failure hepatic
paracetamol overdose survived increased patients failure
Dexatrim cause infarction myocardial
Dexatrim cause infarction
Phenylpropanolamine Dexatrim cause infarction myocardial
Phenylpropanolamine Dexatrim cause infarction
Reserpine produced chewing mice signs dyskinesia tardive
Reserpine produced chewing mice signs dyskinesia
Reserpine produced tremor catalepsy
Reserpine produced tremor
reserpine induced catalepsy
reserpine produced increase tremor
reserpine induced increases tremor catalepsy
reserpine induced increases tremor
reserpine induced catalepsy
reserpine induced catalepsy tremor
reserpine protrusion increases tremor catalepsy
reserpine effects reversed Pretreatment protrusion increases tremor catalepsy
reserpine protrusion increases tremor
reserpine effects reversed Pretreatment protrusion increases tremor
reserpine produces movements different abnormal
reserpine produces movements
reserpine produces considered like tardive
reserpine produces considered like signs dsykinesia
magnesium blockade Neuromuscular
magnesium blockade
sulfate blockade Neuromuscular
sulfate blockade
nifedipine sulfate blockade Neuromuscular
nifedipine sulfate blockade
magnesium sulfate mg administered developed blockade neuromuscular
magnesium sulfate mg administered developed blockade
sulfate mg administered developed blockade neuromuscular
sulfate mg administered developed blockade
nifedipine received patient developed blockade neuromuscular
nifedipine received patient developed blockade
levodopa Worsening dyskinesias
apomorphine dose administration dyskinesia study included patients had dyskinesia
apomorphine dose administration dyskinesia
doxorubicin development failure heart
doxorubicin development failure
fentanyl administration rigidity
fentanyl dose received period case rigidity
oxytocin administration associated intoxication Water
oxytocin administration associated intoxication
oxytocin administration intoxication cases water
oxytocin administration intoxication
Oxytocin administration advocated carried aware symptoms intoxication water
Oxytocin administration advocated carried aware symptoms intoxication
tiazofurin usage associated lesions cerebral
tiazofurin usage associated lesions
methamphetamine induced neurotoxicity
METH reverse dihydroxyphenylalanine show confounded neurotoxicity
METH neurotoxicity
METH effects preserved long METH neurotoxicity
METH development essential neurotoxicity
ammonium Pretreatment doubled increased incoordination
acetate approximately doubled increased incoordination
NH 4 Ac acetate approximately doubled increased incoordination
4 Ac acetate approximately doubled increased incoordination
Ac acetate approximately doubled increased incoordination
NH 4 treatment had doubled increased incoordination
4 treatment had doubled increased incoordination
Ac treatment had doubled increased incoordination
diazepam increased incoordination
NH 4 activity analgesia diazepam incoordination
4 activity analgesia diazepam incoordination
Ac activity analgesia diazepam incoordination
NH verapamil mg activity analgesia diazepam incoordination
4 Ac verapamil mg activity analgesia diazepam incoordination
Ac verapamil mg activity analgesia diazepam incoordination
diazepam incoordination
naproxen due necrosis Renal
naproxen due necrosis papillary
naproxen due necrosis
naproxen therapy institution developed necrosis renal
naproxen therapy institution developed necrosis papillary
naproxen therapy institution developed necrosis
naproxen therapy institution developed necrosis RPN
All induced nodosum erythema
All induced nodosum
trans All induced nodosum erythema
trans All induced nodosum
retinoic acid trans All induced nodosum erythema
retinoic acid trans All induced nodosum
acid trans All induced nodosum erythema
acid trans All induced nodosum
all acid associated nodosum Erythema
all acid associated nodosum
trans acid associated nodosum Erythema
trans acid associated nodosum
retinoic acid associated nodosum Erythema
retinoic acid associated nodosum
acid associated nodosum Erythema
acid associated nodosum
ATRA acid associated nodosum Erythema
ATRA acid associated nodosum
ATRA therapy developed nodosum erythema
ATRA therapy developed nodosum
ATRA therapy developed nodules erythematous
ATRA therapy developed nodules
ATRA therapy developed nodules Fever
ATRA seemed etiology nodosum erythema
ATRA seemed etiology nodosum
ATRA effective induced nodosum erythema
ATRA effective induced nodosum
ziprasidone induced syndrome Neuroleptic
ziprasidone induced syndrome malignant
ziprasidone induced syndrome
ziprasidone use associated syndrome neuroleptic
ziprasidone use associated syndrome malignant
ziprasidone use associated syndrome
ziprasidone use associated syndrome NMS
ziprasidone drugs cause associated NMS
ziprasidone dose developed signs NMS
ziprasidone due NMS
Hydrocortisone hypertension
hydrocortisone rise
hydrocortisone rise pressure in
hydrocortisone rise pressure resting
hydrocortisone rise pressure blood
hydrocortisone rise pressure
lignocaine involving anaesthesia back Leg
lignocaine involving anaesthesia back Leg and
lignocaine involving anaesthesia back
lignocaine involving anaesthesia back pain
lignocaine use associated Leg
lignocaine use associated Leg and
lignocaine use associated Leg /
lignocaine use associated Leg or
lignocaine use associated Leg pain back
lignocaine use associated Leg pain
tamoxifen use association cancer endometrial
tamoxifen use association cancer
tamoxifen received Women likely have cancer endometrial
tamoxifen received Women likely have cancer
tamoxifen received had cancer endometrial
tamoxifen received had cancer
tamoxifen received had Women had those cancer endometrial
tamoxifen received had Women had those cancer
tamoxifen role suggest cancer endometrial
tamoxifen role suggest cancer
tamoxifen treated women diagnosed cancers Endometrial
tamoxifen treated women diagnosed cancers
lead course expression hypertension
lead rats increased reduced hypertension
lead NOx hypertension
lead hypertension
lead inactivation actions stress associated hypertension
cyclophosphamide mice mediators expression induced cystitis
CYP expression induced cystitis
cyclophosphamide cystitis
CYP cyclophosphamide cystitis
CYP VIP induced cystitis
Tac nephrotoxicity
Tac toxicity CsA CsA nephrotoxicity
CsA nephrotoxicity
CsA CsA nephrotoxicity
methadone treated patients prolongation Syncope
methadone treated patients prolongation Syncope QT
methadone treated patients prolongation
methadone effect caused attribute episodes syncope
methadone dose syncope
methadone treated subjects had interval prolonged
methadone treated subjects had interval QTc
methadone treated subjects had interval
methadone dose mg associated odds syncope
Methadone associated prolongation reporting syncope
Methadone associated prolongation QT
Methadone associated prolongation
Prednisolone induced caused dysfunction muscle
Prednisolone induced caused dysfunction
prednisolone dysfunction dose derives atrophy muscle
prednisolone dysfunction dose derives atrophy
suprofen associated development failure acute
suprofen associated development failure renal
suprofen associated development failure
suprofen causes declines acute
suprofen causes declines
suprofen causes declines function in
suprofen causes declines function renal
suprofen causes declines function
dexamethasone induced hypertension
dexamethasone assess hypertension
dex dexamethasone assess hypertension
dex hypertension
dex 392 + superoxide hypertension
dex < 0001 392 + superoxide hypertension
dexamethasone induced hypertension
aminonucleoside existing captopril Effect proteinuria
puromycin aminonucleoside invoked proteinuria
aminonucleoside invoked proteinuria
Glyceryl trinitrate induces attacks migraine
Glyceryl trinitrate induces aura without
Glyceryl trinitrate induces aura
trinitrate induces attacks migraine
trinitrate induces aura without
trinitrate induces aura
nitric oxide involved mechanisms migraine
nitric oxide involved aura without
nitric oxide involved aura
oxide involved mechanisms migraine
oxide involved aura without
oxide involved aura
NO oxide involved mechanisms migraine
NO oxide involved aura without
NO oxide involved aura
bendrofluazide Amelioration hypokalemia
bendrofluazide treatment hypokalemia
alpha induced mice Changes liver hepatoma
benzene Changes liver hepatoma
hexachloride benzene Changes liver hepatoma
alpha induced Peroxisomes lesions hepatomas
benzene hexachloride examined induced Peroxisomes lesions hepatomas
hexachloride examined induced Peroxisomes lesions hepatomas
prostaglandin E inhibition dose induced hyperalgesia
E inhibition dose induced hyperalgesia
2 E inhibition dose induced hyperalgesia
8 induced hyperalgesia
bromo monophosphate hyperalgesia
cyclic monophosphate hyperalgesia
adenosine monophosphate hyperalgesia
monophosphate hyperalgesia
haloperidol sensitization impairment cognitive
haloperidol sensitization impairment
haloperidol administration observed Impairment
haloperidol administration observed Impairment function of
haloperidol administration observed Impairment function cognitive
haloperidol administration observed Impairment function
Haloperidol produced profile impairment cognitive
Haloperidol produced profile impairment
adriamycin mitochondria impairment Structural
adriamycin mitochondria impairment Structural and
adriamycin mitochondria impairment Structural functional
adriamycin mitochondria impairment
adriamycin mitochondria of
adriamycin mitochondria
ADR treatment caused arrhythmias characterized bradycardia
ADR effects involve impairment mitochondrial
ADR effects involve impairment structural
ADR effects involve impairment structural and
ADR effects involve impairment structural functional
ADR effects involve impairment
metoclopramide induced pointes de Torsade
metoclopramide induced pointes de
metoclopramide induced pointes
metoclopramide administration developed pointes torsade
metoclopramide administration developed pointes de
metoclopramide administration developed pointes
erythromycin cisapride given pointes de torsade
erythromycin cisapride given pointes de
erythromycin cisapride given pointes
cisapride given pointes de torsade
cisapride given pointes de
cisapride given pointes
metoclopramide provokes torsade
metoclopramide provokes torsade clinically de
metoclopramide provokes torsade clinically pointes
Metoclopramide used patients risk pointes torsade
Metoclopramide used patients risk pointes de
Metoclopramide used patients risk pointes
ifosfamide function impaired
ifosfamide function renal
ifosfamide function
ifosfamide anuria
ifosfamide sixty developed anuria
Ifosfamide drug nephrotoxic
Ifosfamide drug tubulopathies
ifosfamide due anuria
ifosfamide use recommend patients pretreated chemotherapy nephrotoxic
edrophonium min stability provided kg induced bradycardias
edrophonium induced bradycardias
Cefotetan induced anemia hemolytic
Cefotetan induced anemia
desipramine IP produce hypotension
desipramine IP produce hypotension bradycardia
CaCl group incidence arrhythmias ventricular
CaCl group incidence arrhythmias
2 group incidence arrhythmias ventricular
2 group incidence arrhythmias
lithium case pathology insipidus diabetes
lithium case pathology insipidus
lithium case reported insipidus diabetes
lithium case reported insipidus
ouabain administration falls conclude disease failure left
ouabain administration falls conclude disease failure left end ventricular
ouabain administration falls conclude disease failure left end
ouabain administration falls volume diastolic
ouabain administration falls volume
ouabain administration falls
Oxytocin uterotonic cause hypotension
Oxytocin attributed hypotension
oxytocin response Hypotension
Pentamidine isethionate associated pointes torsade
Pentamidine isethionate associated pointes de
Pentamidine isethionate associated pointes
isethionate associated pointes torsade
isethionate associated pointes de
isethionate associated pointes
Pentamidine induced related pointes torsade
Pentamidine induced related pointes de
Pentamidine induced related pointes
pentamidine occurred pointes Torsade
pentamidine occurred pointes de
pentamidine occurred pointes
pentamidine discontinuation recognized treated pointes Torsade
pentamidine discontinuation recognized treated pointes de
pentamidine discontinuation recognized treated pointes
diltiazem threatening induced tetany
diltiazem infusion developed tetany
diltiazem administration accompany life tetany
propofol controlled Reduction pain
propofol injection Pain
propofol pain
propofol infusion starting infusing prevented pain
propofol caused pain
propofol infusion scale four using evaluated pain
propofol TCI anaesthesia induction achieved reduction pain
propofol pain
cyclophosphamide used damage heart
cyclophosphamide used damage
mitoxantrone cyclophosphamide used damage heart
mitoxantrone cyclophosphamide used damage
bupropion release associated Seizure
bupropion use describes seizure
bupropion use weeks experienced seizure
bupropion risk seizures
scopolamine induced amnesia
scopolamine amnesia
phenobarbital therapy term Hepatonecrosis cholangitis
Phenobarbital has believed indicate development disease liver
Phenobarbital has believed indicate development disease
PB Phenobarbital has believed indicate development disease liver
PB Phenobarbital has believed indicate development disease
PB indicate development disease liver
PB indicate development disease
PB associated damage liver
PB associated damage
haloperidol models catalepsy
reserpine model catalepsy models akinesia
gentamicin died failure acute
gentamicin died failure renal
gentamicin died failure
caffeine pretreatment related case tachycardia ventricular
caffeine pretreatment related case tachycardia
caffeine used improve duration seizure
caffeine used tolerated reports ectopy ventricular
caffeine used tolerated reports ectopy
caffeine administration developed bigeminy runs tachycardia ventricular
caffeine administration developed bigeminy runs tachycardia
carbamazepine induced block patient bradycardia
carbamazepine induced block patient bradycardia atrioventricular
carbamazepine induced block
carbamazepine overdose setting developed tachycardias sinus
carbamazepine overdose setting developed tachycardias
carbamazepine levels elevated developed threatening delay bradyarrhythmias
carbamazepine levels elevated developed threatening delay bradyarrhythmias atrioventricular
carbamazepine levels elevated developed threatening delay conduction
carbamazepine levels elevated developed threatening delay
vitamin C increase risk cardiovascular
vitamin C increase risk disease
C increase risk cardiovascular
C increase risk disease
vitamin intake relation examine disease cardiovascular
vitamin intake relation examine disease
C intake relation examine disease cardiovascular
C intake relation examine disease
vitamin intake relation mortality disease cardiovascular
vitamin intake relation mortality disease
C intake relation mortality disease cardiovascular
C intake relation mortality disease
vitamin intake quintiles 0 < trend P 1 adjustment factors cardiovascular
vitamin intake quintiles 0 < trend P 1 adjustment factors disease
C intake quintiles 0 < trend P 1 adjustment factors cardiovascular
C intake quintiles 0 < trend P 1 adjustment factors disease
vitamin intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease cardiovascular
vitamin intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease
C intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease cardiovascular
C intake quintiles 0 < trend P 1 type medication intakes carotene mortality adjusted risks disease
Vitamin intake unrelated disease cardiovascular
Vitamin intake unrelated disease
C intake unrelated disease cardiovascular
C intake unrelated disease
vitamin intake associated risk mortality cardiovascular
vitamin intake associated risk mortality disease
C intake associated risk mortality cardiovascular
C intake associated risk mortality disease
trihexyphenidyl Bradycardia
hydrochloride Bradycardia
heparin therapy receiving patients thromboembolism induced thrombocytopenia
heparin associated complication thromboembolism induced thrombocytopenia
heparin therapy initiation days occurring ischemia thrombi occlusion arterial
heparin therapy initiation days occurring ischemia thrombi occlusion
heparin therapy initiation days preceded thrombocytopenia
heparin factor relating thromboembolism thrombocytopenia
Prostaglandin E hyperactivity bladder
Prostaglandin E hyperactivity
E hyperactivity bladder
E hyperactivity
2 E hyperactivity bladder
2 E hyperactivity
flumazenil group nausea vomiting
flumazenil group nausea
flumazenil group nausea
azathioprine therapy injury cholestasis
azathioprine therapy injury bile
azathioprine therapy injury duct
azathioprine therapy injury
azathioprine therapy initiation developed features cholestasis
azathioprine case cholestasis
azathioprine case cholestasis associated evidence injury bile
azathioprine case cholestasis associated evidence injury duct
azathioprine case cholestasis associated evidence injury
cefotetan use associated anemia hemolytic
cefotetan use associated anemia
cefotetan cephalosporins associated anemia hemolytic
cefotetan cephalosporins associated anemia
cefotetan cases anemias hemolytic
cefotetan cases anemias
cefotetan prophylactically received patients 10 cases anemias hemolytic
cefotetan prophylactically received patients 10 cases anemias
MA induced hyperthermia
MA ameliorate induced damage neuronal
MA ameliorate induced damage
Methamphetamine causes alterations pathways display aggressiveness
methamphetamine abusers common suffer patients reported behaviors Aggressive
methamphetamine abusers common suffer patients reported behaviors
methamphetamine abusers common suffer disorders psychiatric
methamphetamine abusers common suffer disorders
METH abusers common suffer patients reported behaviors Aggressive
METH abusers common suffer patients reported behaviors
METH abusers common suffer disorders psychiatric
METH abusers common suffer disorders
METH injections increased aggressiveness
METH secondary increase aggressiveness
Chloroquine block blindness
chloroquine ingestion presented deterioration dizziness
chloroquine ingestion presented deterioration fatiguability
chloroquine ingestion presented deterioration dizziness progressing attacks syncopal
chloroquine ingestion presented deterioration dizziness progressing attacks
chloroquine ingestion presented deterioration dyspnoea
chloroquine retinopathy features revealed revealed features failure heart
chloroquine retinopathy features revealed revealed features failure
chloroquine retinopathy features revealed revealed pattern right
chloroquine retinopathy features revealed revealed pattern bundle
chloroquine retinopathy features revealed revealed pattern branch
chloroquine retinopathy features revealed revealed pattern block
chloroquine retinopathy
chloroquine discontinuation resolved failure heart
chloroquine discontinuation resolved failure
contrast media Risk nephropathy
media Risk nephropathy
contrast media reports nephropathy
media reports nephropathy
contrast media reports nephropathy CIN
media reports nephropathy CIN
iohexol iopromide incidence CIN
contrast media CIN
media CIN
CM media CIN
CM type compared determined incidence CIN
iopromide incidence CIN
CM dosage received those 33 patients CIN
CM dosage received those increased those received difference incidence CIN
CM dosages related CIN incidence difference received those increased those 33 patients CIN
CM dosages related CIN
CM type depends depends needed reversible CIN
hepatitis antigen born infants done following screening B hepatitis
hepatitis antigen born infants done following screening B
B antigen born infants done following screening B hepatitis
B antigen born infants done following screening B
surface antigen born infants done following screening B hepatitis
surface antigen born infants done following screening B
antigen born infants done following screening B hepatitis
antigen born infants done following screening B
hepatitis antigen born infants done following administration dose hepatitis
hepatitis antigen born infants done following administration dose B
B antigen born infants done following administration dose hepatitis
B antigen born infants done following administration dose B
surface antigen born infants done following administration dose hepatitis
surface antigen born infants done following administration dose B
antigen born infants done following administration dose hepatitis
antigen born infants done following administration dose B
hepatitis antigen born infants done following administration globulin hepatitis
hepatitis antigen born infants done following administration globulin B
B antigen born infants done following administration globulin hepatitis
B antigen born infants done following administration globulin B
surface antigen born infants done following administration globulin hepatitis
surface antigen born infants done following administration globulin B
antigen born infants done following administration globulin hepatitis
antigen born infants done following administration globulin B
hepatitis antigen born infants received globulin hepatitis
hepatitis antigen born infants received globulin B
B antigen born infants received globulin hepatitis
B antigen born infants received globulin B
surface antigen born infants received globulin hepatitis
surface antigen born infants received globulin B
antigen born infants received globulin hepatitis
antigen born infants received globulin B
doxorubicin protects demonstrate apoptosis extent failure heart
doxorubicin protects demonstrate apoptosis extent failure
enflurane anesthetics associated allergic injury hepatic
enflurane anesthetics associated allergic injury
halothane exposure both injury hepatic
halothane exposure both injury
isoflurane enflurane anesthetics associated allergic injury hepatic
isoflurane enflurane anesthetics associated allergic injury
Halothane hepatitis
halothane patients hepatitis
enflurane produce similar that hepatitis
halothane hepatitis
halothane administration subsequent produce similar that hepatitis
isoflurane / enflurane produce similar that hepatitis
Myocet improves index doxorubicin reducing neutropenia
doxorubicin reducing neutropenia
cyclophosphamide used provides improves index doxorubicin reducing neutropenia
puromycin aminonucleoside antithrombin effects nephrosis
aminonucleoside antithrombin effects nephrosis
puromycin aminonucleoside rats nephrosis
aminonucleoside rats nephrosis
Risperidone disturbances visual
Risperidone disturbances
risperidone starting appeared disturbances visual
risperidone starting appeared disturbances
Risperidone administration continued wore disturbances visual
Risperidone administration continued wore disturbances
diltiazem overdose arrest asystolic
diltiazem overdose arrest cardiac
diltiazem overdose arrest
diltiazem overdose
diltiazem nitrate g 8 overdose
diltiazem therapy overdose onset asystole
diltiazem therapy overdose
diltiazem overdose considered early cases arrest cardiac
diltiazem overdose considered early cases arrest
diltiazem overdose
verapamil fibrillation atrial
verapamil fibrillation
verapamil administered evaluate mechanisms promotion AF
Verapamil caused promotion AF
Verapamil caused increasing mean duration induced AF
verapamil shortened mean decreased AF
verapamil caused that similar produced affect ERP length AF
verapamil caused that similar produced affect ERP duration AF
verapamil failed promote AF
verapamil promoted AF
Verapamil AF
cocaine actions stimulatory convulsive
cocaine SM convulsions
cis predicted included hypercalcemia
RA levels cis predicted included hypercalcemia
Mitomycin C associated syndrome hemolytic
Mitomycin C associated syndrome uremic
Mitomycin C associated syndrome
C associated syndrome hemolytic
C associated syndrome uremic
C associated syndrome
Mitomycin C associated Syndrome Hemolytic
Mitomycin C associated Syndrome Uremic
Mitomycin C associated Syndrome
C associated Syndrome Hemolytic
C associated Syndrome Uremic
C associated Syndrome
Mitomycin C associated Syndrome HUS
C associated Syndrome HUS
mitomycin treatment associated failure renal
mitomycin treatment associated failure
C treatment associated failure renal
C treatment associated failure
mitomycin treatment start mth 8 develops failure renal
mitomycin treatment start mth 8 develops failure
C treatment start mth 8 develops failure renal
C treatment start mth 8 develops failure
mitomycin treatment start mth 8 develops % failure renal
mitomycin treatment start mth 8 develops % failure
C treatment start mth 8 develops % failure renal
C treatment start mth 8 develops % failure
mitomycin C developed failure renal
mitomycin C developed failure
C developed failure renal
C developed failure
ciprofloxacin treatment described followed failure acute
ciprofloxacin treatment described followed failure renal
ciprofloxacin treatment described followed failure
ciprofloxacin diagnosis supports followed improvement induced failure acute
ciprofloxacin diagnosis supports followed improvement induced failure renal
ciprofloxacin diagnosis supports followed improvement induced failure
echothiophate drops use developed presented weakness muscle
echothiophate drops use developed presented weakness
iodide drops use developed presented weakness muscle
iodide drops use developed presented weakness
levodopa pallidotomy dyskinesias
levodopa pallidotomy dyskinesias LID
levodopa responsiveness found was correlation improvement LID
levodopa responsiveness responsiveness found was correlation improvement LID
levodopa responsiveness outcome signs LID
levodopa responsiveness outcome correlations volume dyskinesias
levodopa responsiveness value indicate dyskinesias
vigabatrin patients electroretinography oculography Electro attributed constriction visual
vigabatrin patients electroretinography oculography Electro attributed constriction field
vigabatrin patients electroretinography oculography Electro attributed constriction
vigabatrin associated thought constriction visual
vigabatrin associated thought constriction field
vigabatrin associated thought constriction
vigabatrin patients fields attributed loss visual
vigabatrin patients fields attributed loss field
vigabatrin patients fields attributed loss
vigabatrin therapy associated appears constriction visual
vigabatrin therapy associated appears constriction field
vigabatrin therapy associated appears constriction
Diazepam facilitates bradycardia
adrenaline infusion produced bradycardia
diazepam rats pretreatment enhance adrenaline induced bradycardia
adrenaline change effect causing pretreatment enhance adrenaline induced bradycardia
adrenaline induced bradycardia
diazepam enhancement adrenaline induced bradycardia
adrenaline induced bradycardia
diazepam acts facilitate bradycardia
trazodone dose block heart
trazodone dose block
trazodone dose receiving minutes developed block heart
trazodone dose receiving minutes developed block
D caused syndrome nephrotic
D caused syndrome
Penicillamine caused syndrome nephrotic
Penicillamine caused syndrome
D caused proteinuria
Penicillamine caused proteinuria
fluoxetine hydrochloride induced hyperprolactinemia
hydrochloride induced hyperprolactinemia
fluoxetine hydrochloride induced hyperprolactinemia effects model adenomyosis
hydrochloride induced hyperprolactinemia effects model adenomyosis
fluoxetine hydrochloride induced induction adenomyosis
hydrochloride induced induction adenomyosis
fluoxetine caused hyperprolactinemia
fluoxetine caused adenomyosis
Fluoxetine given produce hyperprolactinemia
fluoxetine receiving group revealed cases adenomyosis
Methimazole induced jaundice cholestatic
Methimazole induced jaundice
methimazole had jaundice itching
dipivalyl thrombosis vein
dipivalyl thrombosis
epinephrine thrombosis vein
epinephrine thrombosis
dipivalyl epinephrine started day seeing acquired thrombosis vein
dipivalyl epinephrine started day seeing acquired thrombosis
epinephrine started day seeing acquired thrombosis vein
epinephrine started day seeing acquired thrombosis
verapamil therapy hypotension adrenergic failure cardiac
verapamil therapy hypotension adrenergic failure
verapamil therapy hypotension bradycardia
beta verapamil therapy hypotension bradycardia
adrenergic hypotension bradycardia
blocking developed failure adrenergic hypotension bradycardia
drugs blocking developed failure adrenergic hypotension bradycardia
verapamil therapy hypotension
beta verapamil therapy hypotension
adrenergic hypotension
blocking developed failure adrenergic hypotension
drugs blocking developed failure adrenergic hypotension
beta verapamil therapy hypotension adrenergic failure cardiac
beta verapamil therapy hypotension adrenergic failure
adrenergic failure cardiac
adrenergic failure
blocking developed failure cardiac
blocking developed failure
drugs blocking developed failure cardiac
drugs blocking developed failure
prazosin blockade 2 occurs hypotension Orthostatic
prazosin blockade 2 occurs hypotension
prazosin treated hypotension orthostatic
prazosin treated hypotension
prazosin dosing performed produce hypotension orthostatic
prazosin dosing performed produce hypotension
Abbott responses bradycardia
53693 Abbott responses bradycardia
noradrenaline i micrograms responses bradycardia
cirazoline responses bradycardia
cirazoline effects bradycardia
Abbott effects similar greater bradycardia
53693 Abbott effects similar greater bradycardia
noradrenaline accompanied bradycardia
iron dextran infusion associated syndrome Value methylprednisolone prevention arthralgia
dextran infusion associated syndrome Value methylprednisolone prevention arthralgia
amphetamine use setting woman syndrome left
amphetamine use setting woman syndrome ventricular
amphetamine use setting woman syndrome apical
amphetamine use setting woman syndrome ballooning
amphetamine use setting woman syndrome
amphetamine use setting woman syndrome cardiomyopathy Takotsubo
amphetamine use setting woman syndrome cardiomyopathy
amphetamine use occurring syndrome apical
amphetamine use occurring syndrome ballooning
amphetamine use occurring syndrome
Levodopa induced dyskinesia
Levodopa alleviated dyskinesia
levodopa induced dyskinesias
flumazenil administration Seizure
flumazenil administration patient seizure occurrence tonic
flumazenil administration patient seizure clonic
flumazenil administration patient seizure
levodopa dyskinesias
propofol sedation underwent dementia delirium
amikacin nephrotoxicity
amikacin associated nephrotoxicity
amikacin efficacy increase means nephrotoxicity
amphetamine diagnosis service patients relationship catecholamines symptoms psychotic
amphetamine diagnosis service patients relationship catecholamines symptoms
amphetamine diagnosis service patients relationship examine interviewed psychosis
cocaine relationship catecholamines symptoms psychotic
cocaine relationship catecholamines symptoms
cocaine relationship examine interviewed psychosis
Methamphetamine levels related scores rating hyperkinesia
amphetamine Methamphetamine levels related scores rating hyperkinesia
thiopentone 4 mg that Somewhat slower i found lasted occurred apnoea
midazolam mg effect inducing sleep kg found lasted occurred apnoea
midazolam group found lasted occurred apnoea
midazolam group occurred apnoea
amikacin receiving patients associated outcome nephrotoxicity
amikacin treated patients Data analyzed factors associated nephrotoxicity
malondialdehyde dependence oxypurines nucleosides ischemia cerebral
malondialdehyde dependence oxypurines nucleosides ischemia
nifedipine induced telangiectasia
nifedipine starting months developed telangiectasia
Adalat nifedipine starting months developed telangiectasia
amlodipine commenced recurrence telangiectasia
nondepolarizing blocking implicated cause weakness muscle
nondepolarizing blocking implicated cause weakness
neuromuscular nondepolarizing blocking implicated cause weakness muscle
neuromuscular nondepolarizing blocking implicated cause weakness
blocking implicated cause weakness muscle
blocking implicated cause weakness
agents implicated cause weakness muscle
agents implicated cause weakness
ND agents implicated cause weakness muscle
ND agents implicated cause weakness
NMBA ND agents implicated cause weakness muscle
NMBA ND agents implicated cause weakness
ND discontinuation weakness
NMBAs patients insufficiency developed weakness
ND likely junction pathology due weakness
NMBA ND likely junction pathology due weakness
ND likely junction pathology
ND likely junction at
ND likely junction both
ND likely junction the
ND likely junction neuromuscular
ND likely junction
NMBA ND likely junction pathology
NMBA ND likely junction at
NMBA ND likely junction both
NMBA ND likely junction the
NMBA ND likely junction neuromuscular
NMBA ND likely junction
doxorubicin cycle fibrillation atrial
doxorubicin cycle fibrillation
cimetidine taking impotence
cimetidine replaced disappeared developed impotence
hydroxychloroquine chloroquine used found case drugs attributable chorioretinopathy
ouabain injection intermittent induced arrhythmia
adrenaline infusion induced arrhythmia Adrenaline
adrenaline infusion induced arrhythmia
adrenaline digitalis cibenzoline arrhythmias
adrenaline digitalis arrhythmias
adrenaline suppress needed dose - cibenzoline suppressed induced v arrhythmia
adrenaline arrhythmias
adrenaline digitalis arrhythmia
thiopental produced involvement reversal paralysis respiratory
thiopental produced involvement reversal paralysis
thiopental induced paralysis respiratory
thiopental induced paralysis
thiopental produced paralysis respiratory
thiopental produced paralysis
nicotine mechanisms induced hyperactivity locomotor
nicotine mechanisms induced hyperactivity
nicotine hyperactivity locomotor
nicotine hyperactivity
nicotine treated develop hyperactivity locomotor
nicotine treated develop hyperactivity
nicotine develop hyperactivity locomotor
nicotine develop hyperactivity
Prostaglandin D had action hyperalgesic
D had action hyperalgesic
2 had action hyperalgesic
prostaglandin D that lasted showed effect hyperalgesic
D that lasted showed effect hyperalgesic
2 D that lasted showed effect hyperalgesic
Prostaglandin E showed effect hyperalgesic
E showed effect hyperalgesic
2 E showed effect hyperalgesic
prostaglandin D effect hyperalgesic
D effect hyperalgesic
2 D effect hyperalgesic
prostaglandin induced blocked hyperalgesia
E 2 prostaglandin induced blocked hyperalgesia
2 prostaglandin induced blocked hyperalgesia
prostaglandin D hyperalgesia
D hyperalgesia
2 hyperalgesia
prostaglandin 2 hyperalgesia
E hyperalgesia
2 hyperalgesia
chondroitin sulfate derivative elicit response hypotensive
sulfate derivative elicit response hypotensive
Valproic I course biomarkers toxicity liver
Valproic I course biomarkers toxicity
acid I course biomarkers toxicity liver
acid I course biomarkers toxicity
valproic levels biomarkers toxicity liver
valproic levels biomarkers toxicity
acid levels biomarkers toxicity liver
acid levels biomarkers toxicity
VPA relationship was determine stress hepatotoxicity
VPA treated Sprague stress hepatotoxicity
VPA results steatosis
VPA results measured IsoP precedes onset necrosis
Topiramate induced nephrolithiasis
topiramate cases nephrolithiasis
indomethacin due anemia aplastic
indomethacin due anemia
indomethacin implicated cause anemia aplastic
indomethacin implicated cause anemia
indomethacin allopurinol other given described case anemia aplastic
indomethacin allopurinol other given described case anemia
indomethacin test substantiates role drug causing anemia aplastic
indomethacin test substantiates role drug causing anemia
reserpine induced dyskinesia
reserpine role dyskinesia
alfentanil induced rigidity muscle
alfentanil induced rigidity
alfentanil acting attenuated produced rigidity muscle
alfentanil acting attenuated produced rigidity
alfentanil produced rigidity
alfentanil followed ketanserin received animals motionless absence rigidity
alfentanil receiving animals motionless absence rigidity
epinephrine induced ischemia myocardial
epinephrine induced ischemia
epinephrine eliciting ischemia myocardial
epinephrine eliciting ischemia
epinephrine produced ischemia myocardial
epinephrine produced ischemia
epinephrine induced ischemia myocardial
epinephrine induced ischemia
epinephrine volume product rate Exercise marked ischemia myocardial
epinephrine volume product rate Exercise marked ischemia
phenylpropanolamine associated hemorrhage Cerebral
phenylpropanolamine associated hemorrhage
caffeine associated hemorrhage Cerebral
caffeine associated hemorrhage
Phenylpropanolamine drug associated effects stroke
PPA Phenylpropanolamine drug associated effects stroke
PPA caffeine lead stroke
caffeine lead stroke normotensive rats hypertensive
PPA caffeine lead stroke normotensive rats hypertensive
caffeine administration lead hypertension
caffeine administration lead hypertension normotensive animals hypertensive
PPA administration lead hypertension
PPA administration lead hypertension normotensive animals hypertensive
PPA caffeine lead hemorrhage cerebral
PPA caffeine lead hemorrhage
caffeine lead hemorrhage cerebral
caffeine lead hemorrhage
caffeine lead hemorrhage animals hypertensive
PPA caffeine lead hemorrhage animals hypertensive
ouabain arrhythmia
levofloxacin associated Seizures
levofloxacin drug initiating developed seizures
levofloxacin drug levofloxacin induced seizures
levofloxacin drug initiating developed seizures
levofloxacin induced seizures
levofloxacin cases RESULTS induced reported seizures
ethinyl estradiol acid hydroxylation sulfation cholestasis
estradiol acid hydroxylation sulfation cholestasis
chlorthalidone phase associated frequency beats ventricular
chlorthalidone phase associated frequency beats ectopic
chlorthalidone phase associated frequency beats
quinine ingestion associated syndrome Hemolytic
quinine ingestion associated syndrome uremic
quinine ingestion associated syndrome
quinine ingestion syndrome Hemolytic
quinine ingestion syndrome uremic
quinine ingestion syndrome
Quinine occurs associated hemolytic
Quinine occurs syndrome uremic
Quinine occurs syndrome
isoflurane function hypotension
isoflurane effect hypotension
isoflurane inspired concentration increasing min / 236 induced Hypotension
isoflurane induced hypotension
labetalol induced Effects hypotension
isoflurane induced Effects hypotension
labetalol induced hypotension
labetalol induced isoflurane group hypotensive
isoflurane induced hypotension
isoflurane group hypotensive
labetalol induced hypotension
isoflurane induced hypotension
scopolamine prevention rats sublethal short amnesia
scopolamine prevention rats sublethal exposed rats response protection amnesia
Fluconazole induced pointes torsade
Fluconazole induced pointes de
Fluconazole induced pointes
fluconazole case torsade
fluconazole case torsade pointes de
fluconazole case torsade pointes
fluconazole case torsade pointes TDP
fluconazole case present discuss causing TDP
fluconazole role discuss present case torsade
fluconazole role discuss present case torsade pointes de
fluconazole role discuss present case torsade pointes
fluconazole role discuss present case torsade pointes TDP
fluconazole role discuss causing TDP
fluconazole commencing days developed TDP
fluconazole had TDP
fluconazole commencing days developed abscess isolated glabrata woman abnormalities was association initiation fluconazole TDP
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed TDP
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had TDP
fluconazole TDP
fluconazole discontinued resolved TDP
fluconazole discontinued resolved indicates relationship use development TDP
fluconazole use relationship indicates resolved TDP
fluconazole use development TDP
fluconazole suggests was etiology explain TDP
fluconazole cause leading TDP
olanzapine induced syndrome Hypomania
olanzapine treatment introduction developed hypomania
lindane convulsions
lindane convulsions incidence produce pretreatment increased incidence convulsions
lindane convulsions incidence increased pretreatment produce incidence convulsions
lindane convulsions
lindane blocked incidence convulsions
lindane treated animals increased P metabolism lindane blocked incidence convulsions
lindane se indicating lindane treated animals increased P metabolism lindane blocked incidence convulsions
PTU associated vasculitis
propylthiouracil vasculitis
PTU propylthiouracil vasculitis
PTU withdrawal symptoms resolution observation made diagnosis propylthiouracil vasculitis
lidocaine cocaine kindled seizures
cocaine kindled seizures
lidocaine seizures
lidocaine seizures development inhibited had effect seizures
cocaine lidocaine seizures
cocaine lidocaine seizures development inhibited had effect seizures
cocaine mortality incidence seizure
lidocaine induced seizures
cocaine kindled lidocaine induced seizures
lidocaine seizures
cocaine lidocaine seizures
amphetamine induced hyperactivity
fluvoxamine treatment potentiated amphetamine induced hyperactivity
nomifensine induced hyperactivity
fluvoxamine remained hyperactivity
clonidine undergoing arrest Cardiac
clonidine undergoing arrest
clonidine reports arrest cardiac
clonidine reports arrest
heparin Delayed induced thrombocytopenia
Heparin BACKGROUND presents thrombocytopenia
heparin exposure presents thrombocytopenia
heparin recognition contribute thrombocytopenia
heparin manifestations thrombocytopenia
heparin thrombocytopenia
heparin exposure included thrombocytopenia
heparin thrombocytopenia
heparin thrombocytopenia
heparin returns initiated thrombocytopenia
carbimazole therapy bupropion Acute
carbimazole therapy bupropion Acute failure liver
carbimazole therapy bupropion Acute failure
bupropion Acute
bupropion Acute failure liver
bupropion Acute failure
bupropion induced hepatotoxicity
carbimazole treatment receiving resulted case is increasing evidence hepatotoxicity
carbimazole treatment receiving resulted failure acute
carbimazole treatment receiving resulted failure liver
carbimazole treatment receiving resulted failure
bupropion induced hepatotoxicity
bupropion while receiving resulted case is increasing evidence hepatotoxicity
bupropion induced hepatotoxicity evidence increasing is case resulted failure acute
bupropion induced hepatotoxicity evidence increasing is case resulted failure liver
bupropion induced hepatotoxicity evidence increasing is case resulted failure
bupropion while receiving resulted failure acute
bupropion while receiving resulted failure liver
bupropion while receiving resulted failure
bupropion given drugs hepatotoxic
bupropion induced insult acute
bupropion induced insult liver
bupropion induced insult
azelastine placebo significantly group increased Drowsiness perception altered
azelastine placebo significantly group increased Drowsiness perception taste
azelastine placebo significantly group increased Drowsiness perception
azelastine placebo significantly group increased Drowsiness
isoniazid neuropathy
isoniazid dose caused neuropathy
pilocarpine treated analyze occurrence seizures
pilocarpine induced result seizures
KA / pilocarpine induced result seizures
morphine treated Hyperalgesia myoclonus
morphine treated Hyperalgesia
morphine doses treated disease stages patients developed hyperalgesia
morphine doses relationship myoclonus
morphine plays indicates available descriptions relationship myoclonus
morphine doses relationship myoclonus hyperalgesia
morphine plays indicates available descriptions relationship myoclonus hyperalgesia
chlorthalidone administration loss hypokalaemia
Tiopronin due nephritis dermatitis
Tiopronin due due dermatitis
gold thiosulphate due dermatitis due due nephritis dermatitis
gold thiosulphate due dermatitis
Tiopronin due nephritis
Tiopronin group nephritis
lidocaine system role convulsion
lidocaine convulsions
lidocaine convulsions
lidocaine incidence increased treatment L induced convulsions
lidocaine mediator convulsions
tamoxifen women events vascular
tamoxifen women events
tamoxifen women events hypertriglyceridaemia
L patients overactivation dose dyskinesia
dopa overactivation dose dyskinesia
L patients groups supplementary task execution dopa dyskinesia
dopa medication execution dopa dyskinesia
L patients groups supplementary task execution other dyskinesia
dopa medication execution other dyskinesia
L one medication execution dopa dyskinesia
dopa dyskinesia
L one medication execution other dyskinesia
dopa execution other dyskinesia
L movement abnormal
L movement involuntary
L movement
dopa L movement abnormal
dopa L movement involuntary
dopa L movement
L induced dyskinesia
dopa L induced dyskinesia
tolazamide Wernicke
tolazamide abnormality encephalopathy s
tolazamide abnormality encephalopathy
tolazamide treated encephalopathy Wernicke
tolazamide treated encephalopathy Wernicke '
tolazamide treated encephalopathy s
tolazamide treated encephalopathy
tolazamide patient syndrome similarity encephalopathy Wernicke
tolazamide patient syndrome similarity encephalopathy Wernicke '
tolazamide patient syndrome similarity encephalopathy s
tolazamide patient syndrome similarity encephalopathy
methyldopa effect hypotensive
methyldopa neurons microinjection elicits response hypotensive
methyldopa microinjection caused hypotension
methyldopa mediate hypotension
methyldopa mediate cells contribute action hypotensive
methyldopa action contribute cells mediate hypotension
methyldopa action hypotensive
Lamotrigine associated myoclonus
lamotrigine exacerbation appearance jerks myoclonic
lamotrigine exacerbation appearance jerks
lamotrigine exacerbation appearance jerks MJ
LTG exacerbation appearance jerks myoclonic
LTG exacerbation appearance jerks
LTG exacerbation appearance jerks MJ
LTG exacerbated MJ
LTG dose decreased disappeared MJ
LTG exacerbated MJ
LTG exacerbated status myoclonic
LTG exacerbated status
LTG withdrawal ceased status exacerbated MJ
LTG withdrawal ceased status myoclonic
LTG withdrawal ceased status
cisplatin injection induced injury acute
cisplatin injection induced injury renal
cisplatin injection induced injury
paracetamol developed bladder epithelium Papillomas bore carcinomas bladder
paracetamol developed bladder epithelium Papillomas bore carcinomas
paracetamol % treated developed hyperplasia
paracetamol livers study treated revealed hepatocytes resemble those result variety hepatocarcinogens
carrageenan licking models induced hyperalgesia thermal
carrageenan licking models induced hyperalgesia
carrageenan licking models induced hyperalgesia mechanical
carrageenan licking models induced hyperalgesia
capsaicin hyperalgesia thermal
capsaicin hyperalgesia
capsaicin hyperalgesia induced models induced hyperalgesia mechanical
capsaicin hyperalgesia induced models induced hyperalgesia
paclitaxel received suffered edema moderate brain
paclitaxel received suffered edema
paclitaxel total received edema moderate brain
paclitaxel total received edema
haloperidol induced hyperprolactinemia
haloperidol induced hyperprolactinemia
HAL haloperidol induced hyperprolactinemia
isoproterenol Development hypertrophy cardiac
isoproterenol Development hypertrophy
isoproterenol injections rats studied development hypertrophy cardiac
isoproterenol injections rats studied development hypertrophy
ISO isoproterenol injections rats studied development hypertrophy cardiac
ISO isoproterenol injections rats studied development hypertrophy
tranylcypromine interaction syndrome Serotonin
tranylcypromine interaction syndrome
venlafaxine syndrome Serotonin
venlafaxine syndrome
tranylcypromine taking male y venlafaxine interaction resulted syndrome serotonin
tranylcypromine taking male y venlafaxine interaction resulted syndrome
venlafaxine interaction resulted syndrome serotonin
venlafaxine interaction resulted syndrome
Calcitriol therapy suppresses has hypercalcemia
Calcitriol therapy suppresses has hypercalcemia suppression
Calcitriol therapy suppresses has hypercalcemia suppression turnover of
Calcitriol therapy suppresses has hypercalcemia suppression turnover bone
Calcitriol therapy suppresses has hypercalcemia suppression turnover
Calcitriol therapy suppresses has hypercalcemia suppression turnover lead disease adynamic
Calcitriol therapy suppresses has hypercalcemia suppression turnover lead disease bone
Calcitriol therapy suppresses has hypercalcemia suppression turnover lead disease
OCT prevent occurrence hypercalcemia
Ciprofloxacin induced nephritis interstitial
Ciprofloxacin induced nephritis
Ciprofloxacin associated effects nephritis anemia hemolytic
Ciprofloxacin associated effects nephritis anemia
Ciprofloxacin associated effects nephritis interstitial
Ciprofloxacin associated effects nephritis
ciprofloxacin case nephritis interstitial
ciprofloxacin case nephritis
trihexyphenidyl challenge allele slowing mental
trihexyphenidyl challenge allele slowing
trihexyphenidyl dose resulted ratings slowness mental
trihexyphenidyl dose resulted ratings slowness
trihexyphenidyl mg ratings slowness mental
trihexyphenidyl mg ratings slowness
trihexyphenidyl challenge associated slowing mental
trihexyphenidyl challenge associated slowing
puromycin aminonucleoside induced Plasma lipids development syndrome nephrotic
puromycin aminonucleoside induced Plasma lipids development syndrome
aminonucleoside induced Plasma lipids development syndrome nephrotic
aminonucleoside induced Plasma lipids development syndrome
puromycin aminonucleoside induced syndrome nephrotic
puromycin aminonucleoside induced syndrome
aminonucleoside induced syndrome nephrotic
aminonucleoside induced syndrome
puromycin aminonucleoside induced syndrome found lipoproteins alterations due syndrome nephrotic
puromycin aminonucleoside induced syndrome found lipoproteins alterations due syndrome
aminonucleoside induced syndrome found lipoproteins alterations due syndrome nephrotic
aminonucleoside induced syndrome found lipoproteins alterations due syndrome
aminonucleoside or syndrome due alterations lipoproteins found syndrome nephrotic
aminonucleoside or syndrome due alterations lipoproteins found syndrome
aminonucleoside or syndrome nephrotic
aminonucleoside or syndrome
puromycin aminonucleoside administration development syndrome nephrotic
puromycin aminonucleoside administration development syndrome
aminonucleoside administration development syndrome nephrotic
aminonucleoside administration development syndrome
oral therapy complications pretreatment levels factors blood
oral therapy complications pretreatment levels factors coagulation
contraceptive therapy complications pretreatment levels factors blood
contraceptive therapy complications pretreatment levels factors coagulation
diltiazem interaction cisapride related Prolongation
diltiazem interaction cisapride related Prolongation interval of
diltiazem interaction cisapride related Prolongation interval the
diltiazem interaction cisapride related Prolongation interval QT
diltiazem interaction cisapride related Prolongation interval
cisapride related Prolongation
cisapride related Prolongation interval of
cisapride related Prolongation interval the
cisapride related Prolongation interval QT
cisapride related Prolongation interval
azole erythromycin agents reported Prolongation interval death sudden
azole erythromycin agents reported Prolongation interval death cardiac
azole erythromycin agents reported Prolongation interval death
azole erythromycin agents reported Prolongation interval pointes torsades
azole erythromycin agents reported Prolongation interval pointes de
azole erythromycin agents reported Prolongation interval pointes
erythromycin agents reported Prolongation interval pointes torsades
erythromycin agents reported Prolongation interval pointes de
erythromycin agents reported Prolongation interval pointes
azole erythromycin agents reported Prolongation
azole erythromycin agents reported Prolongation interval of
azole erythromycin agents reported Prolongation interval QT
azole erythromycin agents reported Prolongation interval
erythromycin agents reported Prolongation interval death sudden
erythromycin agents reported Prolongation interval death cardiac
erythromycin agents reported Prolongation interval death
erythromycin agents reported Prolongation
erythromycin agents reported Prolongation interval of
erythromycin agents reported Prolongation interval QT
erythromycin agents reported Prolongation interval
MMC m developed failure cardiac
MMC m developed failure
doxorubicin m developed failure cardiac
doxorubicin m developed failure
lithium treatment hypothyroidism
lithium taking developed Hypothyroidism
gentamicin resistance responsible suggested failure acute
gentamicin resistance responsible suggested failure renal
gentamicin resistance responsible suggested failure
gentamicin resistance responsible suggested failure ARF
streptozotocin mellitus diabetes
streptozotocin mellitus
streptozotocin DM
gentamicin ARF
ethambutol due neuropathy Bilateral
ethambutol due neuropathy optic
ethambutol due neuropathy
isoniazid treatment ethambutol due neuropathy Bilateral
isoniazid treatment ethambutol due neuropathy optic
isoniazid treatment ethambutol due neuropathy
pemoline overdose
lithium therapy insipidus nephrogenic
lithium therapy insipidus diabetes
lithium therapy insipidus
lithium induced insipidus nephrogenic
lithium induced insipidus diabetes
lithium induced insipidus
lithium therapy discontinued diagnosed have lithium induced insipidus nephrogenic
lithium therapy discontinued diagnosed have lithium induced insipidus diabetes
lithium therapy discontinued diagnosed have lithium induced insipidus
lithium cessation remained thirsty polyuric
lithium cessation remained showed evidence insipidus nephrogenic
lithium cessation remained showed evidence insipidus diabetes
lithium cessation remained showed evidence insipidus
Lithium considered persisted polyuria
lithium stopped persisted polyuria
Lithium considered insipidus nephrogenic
Lithium considered insipidus diabetes
Lithium considered insipidus
lithium stopped persisted considered insipidus nephrogenic
lithium stopped persisted considered insipidus diabetes
lithium stopped persisted considered insipidus
lithium patients management implications mechanisms insipidus nephrogenic
lithium patients management implications mechanisms insipidus diabetes
lithium patients management implications mechanisms insipidus
rifampin proteinuria
rifampin treated patients 9 found proteinuria
puromycin aminonucleoside subunits targeting expression syndrome nephrotic
puromycin aminonucleoside subunits targeting expression syndrome
aminonucleoside subunits targeting expression syndrome nephrotic
aminonucleoside subunits targeting expression syndrome
PAN treatment induced proteinuria hypoalbuminemia
PAN treatment induced proteinuria ascites
PAN treatment induced proteinuria
PAN associated syndrome nephrotic
PAN associated syndrome
sulphasalazine treatment restarting developed eyes effusion pleural
sulphasalazine treatment restarting developed eyes effusion
sulphasalazine treatment cessation resulted fever effusions pleural
sulphasalazine treatment cessation resulted fever effusions
sulphasalazine treatment cessation resulted initiated remained effusion pleural
sulphasalazine treatment cessation resulted initiated remained effusion
sulphasalazine treatment cessation resulted fever
PGE NGF increased patients OAB
2 PGE NGF increased patients OAB
PGF NGF increased patients OAB
2 alpha PGF NGF increased patients OAB
alpha PGF NGF increased patients OAB
PGE OAB
2 PGE OAB
PGF alpha correlate parameters patients OAB
2 alpha correlate parameters patients OAB
alpha correlate parameters patients OAB
iron dextran induced degeneration
iron dextran induced degeneration neurons of
iron dextran induced degeneration neurons dopaminergic
iron dextran induced degeneration neurons
dextran induced degeneration
dextran induced degeneration neurons of
dextran induced degeneration neurons dopaminergic
dextran induced degeneration neurons
iron animals content detection study degeneration
iron animals content detection study degeneration neurons of
iron animals content detection study degeneration neurons dopaminergic
iron animals content detection study degeneration neurons
dextran animals content detection study degeneration
dextran animals content detection study degeneration neurons of
dextran animals content detection study degeneration neurons dopaminergic
dextran animals content detection study degeneration neurons
iron dextran increase SN causes degeneration
iron dextran increase SN causes degeneration neurons of
iron dextran increase SN causes degeneration neurons dopaminergic
iron dextran increase SN causes degeneration neurons
dextran increase SN causes degeneration
dextran increase SN causes degeneration neurons of
dextran increase SN causes degeneration neurons dopaminergic
dextran increase SN causes degeneration neurons
Methylphenidate induced obsessive
Methylphenidate induced obsessive symptoms compulsive
Methylphenidate induced obsessive symptoms
methylphenidate replaced diminished ensued obsessive
methylphenidate replaced diminished ensued behavior compulsive
methylphenidate replaced diminished ensued behavior
LiCl administration 2 mice led polyuria
everolimus prophylaxis Graft associated incidence syndrome microangiopathy
tacrolimus everolimus prophylaxis Graft associated incidence syndrome sinusoidal
tacrolimus everolimus prophylaxis Graft associated incidence syndrome obstruction
tacrolimus everolimus prophylaxis Graft associated incidence syndrome
tacrolimus everolimus prophylaxis Graft associated incidence syndrome microangiopathy
everolimus prophylaxis Graft associated incidence syndrome sinusoidal
everolimus prophylaxis Graft associated incidence syndrome obstruction
everolimus prophylaxis Graft associated incidence syndrome
pravastatin use associated myopathy inflammatory
pravastatin use associated myopathy
T had effect locomotion irritability
T had increased preference aggression
enalapril assigned Patients RESULTS had likelihood function decreased
enalapril assigned Patients RESULTS had likelihood function renal
enalapril assigned Patients RESULTS had likelihood function
enalapril groups placebo associated function decreased
enalapril groups placebo associated function renal
enalapril groups placebo associated function
diuretic therapy age associated function decreased
diuretic therapy age associated function renal
diuretic therapy age associated function
enalapril group significantly % 32 1 52 associated risk developing function decreased
enalapril group significantly % 32 1 52 associated risk developing function renal
enalapril group significantly % 32 1 52 associated risk developing function
enalapril group significantly % 32 1 52 associated risk developing function decreased
enalapril group significantly % 32 1 52 associated risk developing function renal
enalapril group significantly % 32 1 52 associated risk developing function
enalapril 52 associated risk developing function decreased
enalapril 52 associated risk developing function renal
enalapril 52 associated risk developing function
enalapril group function decreased
enalapril group function renal
enalapril group function
Diuretic therapy associated risk function decreased
Diuretic therapy associated risk function renal
Diuretic therapy associated risk function
Enalapril use caused risk function decreased
Enalapril use caused risk function renal
Enalapril use caused risk function
enalapril group reduced associated risk impairment renal
enalapril group reduced associated risk impairment
scopolamine cholinesterase 247 Effects induced amnesia
NIK Effects induced amnesia
247 Effects induced amnesia
tacrine 247 induced examined amnesia
scopolamine 247 induced examined amnesia
E tacrine 247 induced examined amnesia
2020 effects 247 induced examined amnesia
NIK effects 247 induced examined amnesia
247 induced examined amnesia
scopolamine induced amnesia
scopolamine induced amnesia
NIK 247 improves scopolamine induced amnesia
- 247 improves scopolamine induced amnesia
247 improves scopolamine induced amnesia
capsaicin injection determined obtained stimuli hyperalgesia mechanical
capsaicin injection determined obtained stimuli hyperalgesia
capsaicin injection determined obtained stimuli hyperalgesia allodynia
capsaicin injection reduced hyperalgesia mechanical
capsaicin injection reduced hyperalgesia
capsaicin injection reduced hyperalgesia allodynia
dexamethasone treatment years age dysfunction neurological
dexamethasone treatment years age dysfunction
dexamethasone therapy assess dysfunction neurological
dexamethasone therapy assess dysfunction
dexamethasone treatment showed rate dysfunctions neurological
dexamethasone treatment showed rate dysfunctions
methotrexate accident leukoencephalopathy
methotrexate treated patients identified reports leukoencephalopathy
5 methotrexate treated patients identified reports leukoencephalopathy
fluorouracil 5 methotrexate treated patients identified reports leukoencephalopathy
carmofur fluorouracil 5 methotrexate treated patients identified reports leukoencephalopathy
capecitabine methotrexate treated patients identified reports leukoencephalopathy
scopolamine MEASURES impairment
scopolamine MEASURES impairment recall in
scopolamine MEASURES impairment recall word
scopolamine MEASURES impairment recall
scopolamine induced impairment
scopolamine induced impairment recall in
scopolamine induced impairment recall word
scopolamine induced impairment recall
Calcium toxicity milk
Calcium toxicity alkali
Calcium toxicity alkali syndrome
carbonate toxicity milk
carbonate toxicity alkali
carbonate toxicity alkali syndrome
calcium carbonate describe induced insights hypercalcemia
carbonate describe induced insights hypercalcemia
calcium carbonate describe induced cause milk
calcium carbonate describe alkali
calcium carbonate describe alkali syndrome
carbonate describe induced cause milk
carbonate describe alkali
carbonate describe alkali syndrome
pamidronate intravenously caused hypocalcemia
calcium carbonate amounts precipitated cause CONCLUSION Milk
calcium carbonate amounts precipitated cause syndrome alkali
calcium carbonate amounts precipitated cause syndrome
carbonate amounts precipitated cause CONCLUSION Milk
carbonate amounts precipitated cause syndrome alkali
carbonate amounts precipitated cause syndrome
calcium carbonate amounts precipitated cause hypercalcemia
carbonate amounts precipitated cause hypercalcemia
Pamidronate treatment associated risk hypocalcemia
sirolimus administration association syndrome capillary
sirolimus administration association syndrome leak
sirolimus administration association syndrome
rapamycin sirolimus administration association syndrome capillary
rapamycin sirolimus administration association syndrome leak
rapamycin sirolimus administration association syndrome
sirolimus treatment syndrome capillary
sirolimus treatment syndrome leak
sirolimus treatment syndrome
sirolimus specimen OBSERVATIONS induced leak capillary
sirolimus specimen OBSERVATIONS induced leak
sirolimus specimen OBSERVATIONS induced leak syndrome
sirolimus fold 3 syndrome leak capillary
sirolimus fold 3 syndrome leak
sirolimus fold 3 syndrome
sirolimus effects include fever syndrome capillary
sirolimus effects include fever syndrome leak
sirolimus effects include fever syndrome
diazepam complications Venous
diazepam complications
midazolam complications Venous
midazolam complications
diazepam associated venous
diazepam associated complications
midazolam associated venous
midazolam associated complications
diazepam injection evaluated incidence complications venous
diazepam injection evaluated incidence complications
midazolam diazepam injection evaluated incidence complications venous
midazolam diazepam injection evaluated incidence complications
diazepam frequent complications venous
diazepam frequent complications
midazolam frequent complications venous
midazolam frequent complications
theophylline fenoldopam induced arteritis
fenoldopam induced arteritis
theophylline vasodilators induced Arteritis
fenoldopam vasodilators induced Arteritis
streptozotocin role nephropathy diabetic
streptozotocin role nephropathy
streptozotocin tissues using nephropathy diabetic
streptozotocin tissues using nephropathy
streptozotocin tissues patients diabetic
streptozotocin tissues patients nephropathy
streptozotocin tissues model diabetic
streptozotocin tissues model nephropathy
streptozocin crocin L constituents Effects model disease Alzheimer
streptozocin crocin L constituents Effects model disease Alzheimer '
streptozocin crocin L constituents Effects model disease s
streptozocin crocin L constituents Effects model disease
streptozocin induced disease Alzheimer
streptozocin induced disease Alzheimer '
streptozocin induced disease s
streptozocin induced disease
STZ streptozocin induced disease Alzheimer
STZ streptozocin induced disease Alzheimer '
STZ streptozocin induced disease s
STZ streptozocin induced disease
STZ injected groups Alzheimer
STZ injected groups Alzheimer '
STZ injected groups s
STZ injected groups disease
STZ repeated injected groups Alzheimer
STZ repeated injected groups Alzheimer '
STZ repeated injected groups s
STZ repeated injected groups disease
STZ caused deficits cognitive
STZ caused deficits
STZ caused deficits antagonizing demonstrate disease potential treatment diseases Alzheimer
STZ caused deficits antagonizing demonstrate disease potential treatment diseases Alzheimer '
STZ caused deficits antagonizing demonstrate disease s
STZ caused deficits antagonizing demonstrate disease
streptozotocin caused function reverse mellitus diabetes
streptozotocin caused function reverse mellitus
streptozotocin function investigated rats diabetic
streptozotocin diabetes
cocaine use delirium
cocaine toxicity mechanisms provide Fatal use delirium
cocaine induced delirium
cocaine induced delirium EDDs
cocaine registry compared EDDs
cocaine registry compared delirium
cocaine overdose victims compared EDDs
cocaine overdose victims compared delirium
cocaine concentrations had EDDs
cocaine use disrupts precipitate agitation death sudden
cocaine use disrupts precipitate agitation death
cocaine use coupled disrupts precipitate agitation death sudden
cocaine use coupled disrupts precipitate agitation death
cocaine use disrupts precipitate agitation rhabdomyolysis
cocaine use coupled disrupts precipitate agitation rhabdomyolysis
cocaine use disrupts precipitate agitation delirium
cocaine use coupled disrupts precipitate agitation delirium
cocaine induce sensitization seizures
lidocaine appearance induced convulsions
lidocaine appearance induced convulsions
cocaine that decreased induced convulsions
cocaine that decreased induced appearance induced convulsions
lidocaine administration reversed changes activity convulsive
lidocaine activity convulsive
cocaine lidocaine activity convulsive
lidocaine convulsions
lidocaine seizures
cocaine administration resulting kindling distinct have sensitization seizures
ACTH stimulation dystonia
MSH ACTH stimulation dystonia
succinylcholine induced myalgia postoperative
succinylcholine induced myalgia
succinylcholine used proven agent reduction myalgia postoperative
succinylcholine used proven agent reduction myalgia
corticosteroid therapy resolved pressure elevated
corticosteroid therapy resolved pressure intraocular
corticosteroid therapy resolved pressure
NH 4 mmol CL intraperitonealinjection minutes rats produced coma
4 mmol CL intraperitonealinjection minutes rats produced coma
CL intraperitonealinjection minutes rats produced coma
lignocaine anaesthesia syndrome Cauda
lignocaine anaesthesia syndrome equina
lignocaine anaesthesia syndrome
lignocaine anaesthesia syndrome review cases syndrome cauda
lignocaine anaesthesia syndrome review cases syndrome equina
lignocaine anaesthesia syndrome review cases syndrome
carboplatin dose using induced Anemia
carboplatin application days administered rHuEPO prevented development anemia
cidofovir Use associated failure progressive
cidofovir Use associated failure renal
cidofovir Use associated failure
cidofovir Use associated failure neutropenia
Nicotine potentiation catalepsy
morphine potentiation catalepsy
nicotine catalepsy
morphine induced catalepsy
nicotine Morphine induced dose catalepsy
Morphine induced dose catalepsy
nicotine reduced induced catalepsy
morphine combination reduced induced catalepsy
nicotine morphine induced catalepsy
morphine induced catalepsy
nicotine induced morphine potentiation mediated concluded elicited catalepsy
morphine catalepsy
morphine potentiation mediated concluded elicited catalepsy
N rats Production cancer prostate
N rats Production cancer
nitroso rats Production cancer prostate
nitroso rats Production cancer
N rats Production cancer prostate
N rats Production cancer
methylurea rats Production cancer prostate
methylurea rats Production cancer
N treatments adenocarcinomas prostate
N treatments adenocarcinomas
nitroso treatments adenocarcinomas prostate
nitroso treatments adenocarcinomas
N treatments adenocarcinomas prostate
N treatments adenocarcinomas
methylurea treatments adenocarcinomas prostate
methylurea treatments adenocarcinomas
N treatments adenocarcinomas PAs
nitroso treatments adenocarcinomas PAs
N treatments adenocarcinomas PAs
methylurea treatments adenocarcinomas PAs
testosterone methylurea treatments adenocarcinomas prostate
testosterone methylurea treatments adenocarcinomas
propionate CAS testosterone methylurea treatments adenocarcinomas prostate
propionate CAS testosterone methylurea treatments adenocarcinomas
testosterone methylurea treatments adenocarcinomas PAs
propionate CAS testosterone methylurea treatments adenocarcinomas PAs
TP CAS testosterone methylurea treatments adenocarcinomas prostate
TP CAS testosterone methylurea treatments adenocarcinomas
TP CAS testosterone methylurea treatments adenocarcinomas PAs
TP treated PA
TP acted development cancer prostate
TP acted development cancer
alfentanil anesthesia rigidity muscle
alfentanil anesthesia rigidity
alfentanil prevented MED D induced rigidity muscle
alfentanil prevented MED D induced rigidity
levodopa dyskinesias
Etoposide infarction myocardial
Etoposide infarction
etoposide containing reported occurrence infarction myocardial
etoposide containing reported occurrence infarction
tobramycin netilmicin treated patients proportion occurred Nephrotoxicity
netilmicin treated patients proportion occurred Nephrotoxicity
piperacillin netilmicin four occurred Ototoxicity
piperacillin tobramycin occurred Ototoxicity
tobramycin occurred Ototoxicity
netilmicin four occurred Ototoxicity
tobramycin severe ototoxicity
netilmicin severe ototoxicity
fenoldopam induced hypotension
fenoldopam used induce hypotension
fenoldopam induced + hypotension
fenoldopam increased flow hypotension
nitroprusside cent 8 flow increased fenoldopam induced + hypotension
nitroprusside cent 8 flow hypotension
nitroprusside non arteriolar produce kidney hypotension
cyclooxygenase inhibitors treatment failure infarction stroke
inhibitors treatment failure infarction stroke
cyclooxygenase inhibitors treatment failure myocardial
cyclooxygenase inhibitors treatment failure infarction
inhibitors treatment failure myocardial
inhibitors treatment failure infarction
cyclooxygenase inhibitors treatment failure infarction hypertension
inhibitors treatment failure infarction hypertension
cyclooxygenase inhibitors treatment failure infarction heart
cyclooxygenase inhibitors treatment failure
inhibitors treatment failure infarction heart
inhibitors treatment failure
pilocarpine neurons containing induced seizures
pilocarpine injected studied 1 seizures
pilocarpine intervals 1 seizures
digitalis stage induced arrhythmias ventricular
digitalis stage induced arrhythmias
digitalis stage induced two Using examined determined concentration model arrhythmia
adrenaline stage induced arrhythmias ventricular
adrenaline stage induced arrhythmias
adrenaline stage induced two Using examined determined concentration model arrhythmia
digitalis ligation concentrations arrhythmias
digitalis ligation concentrations arrhythmias
adrenaline concentrations arrhythmias
adrenaline concentrations arrhythmias
adrenaline concentration higher arrhythmia
adrenaline concentration higher those types arrhythmias
scopolamine model amnesia
scopolamine amnesia
levodopa dyskinesias
mannitol lower elevated
mannitol lower elevated ICP
cyclosporine showed decrease therapy secondary nephrotoxicity
cyclosporine dosages cause nephrotoxicity
M % groups treated steroid showed reduction
M % groups treated steroid showed reduction intake of
M % groups treated steroid showed reduction intake food
M % groups treated steroid showed reduction intake
T M % groups treated steroid showed reduction
T M % groups treated steroid showed reduction intake of
T M % groups treated steroid showed reduction intake food
T M % groups treated steroid showed reduction intake
T showed IIa atrophy
T showed IIa atrophy
T C rats performed study showed pronounced atrophy muscle
T C rats performed study showed pronounced atrophy
T pronounced atrophy muscle
T pronounced atrophy
haloperidol induced catalepsy
haloperidol induced catalepsy
Haloperidol challenged catalepsy
haloperidol injections previous attenuated catalepsy
haloperidol mechanisms glutamate induced catalepsy
Acetazolamide induced syndrome Gerstmann
Acetazolamide induced syndrome
acetazolamide case report induced syndrome Gerstmann
acetazolamide case report induced syndrome
oral contraception associated Chorea
contraception associated Chorea
oral contraceptives receiving developed chorea
contraceptives receiving developed chorea
amphetamine induced chorea
oral contraception induced chorea
contraception induced chorea
azithromycin associated hiccups
azithromycin therapy associated hiccups
azithromycin beginning presented hiccups
azithromycin Discontinuation resolved hiccups
baclofen azithromycin Discontinuation resolved hiccups
azithromycin mediated mechanism pathogenesis hiccups
Ketamine elicited psychosis
warfarin trends hemorrhage
warfarin incidence bleeding
haloperidol induced rigidity Muscle
haloperidol induced rigidity
haloperidol rigidity muscle
haloperidol rigidity
valsartan % day mg dose higher incidence drug edema
valsartan % % % day mg dose higher incidence drug edema
amlodipine group higher incidence drug edema
amlodipine % % day mg dose higher incidence drug edema
amlodipine % % % day mg dose higher incidence drug edema
amlodipine % % day mg dose higher incidence drug edema
CLZ ingestion accompanying flush nausea
CLZ ingestion accompanying duration headache
CLZ ingestion accompanying flush facial
CLZ ingestion accompanying flush
5 flourouracil induced syndrome apical
5 flourouracil induced syndrome ballooning
5 flourouracil induced syndrome
flourouracil induced syndrome apical
flourouracil induced syndrome ballooning
flourouracil induced syndrome
fentanyl neurotransmission Involvement rigidity muscular
fentanyl neurotransmission Involvement rigidity
fentanyl anesthesia dose effect well rigidity muscular
fentanyl anesthesia dose effect well rigidity
fentanyl rigidity muscular
fentanyl rigidity
iohexol study comparing effects nephrotoxic
Isoproterenol induces loss correlation injury myocardial
Isoproterenol induces loss correlation injury
isoproterenol demand unknown damage myocardial
isoproterenol demand unknown damage
isoproterenol demand hypotension hyperactivity myocardial
isoproterenol demand hypotension hyperactivity
isoproterenol induced injury integrity alterations explain changes related injury ischaemic
isoproterenol induced injury integrity alterations explain changes related injury
fluocinolone implant treated uveitis patients report incidence pressure elevated
fluocinolone implant treated uveitis patients report incidence pressure intraocular
fluocinolone implant treated uveitis patients report incidence pressure
acetonide implant treated uveitis patients report incidence pressure elevated
acetonide implant treated uveitis patients report incidence pressure intraocular
acetonide implant treated uveitis patients report incidence pressure
FA implant treated uveitis patients report incidence pressure elevated
FA implant treated uveitis patients report incidence pressure intraocular
FA implant treated uveitis patients report incidence pressure
haloperidol antagonist beta induced catalepsy
haloperidol induced catalepsy
haloperidol induced catalepsy
DFP TOTP given chickens exacerbated induced neuropathy
TOTP effects had corticosterone concentrations induced neuropathy
TOTP given chickens exacerbated induced neuropathy
DFP TOTP evident fibers Degenerating
DFP TOTP evident fibers myelinated
DFP TOTP evident fibers
TOTP evident fibers Degenerating
TOTP evident fibers myelinated
TOTP evident fibers
carbon tetrachloride effects hepatotoxic
tetrachloride effects hepatotoxic
CCl tetrachloride effects hepatotoxic
4 CCl tetrachloride effects hepatotoxic
acetaminophen CHCl CCl effects hepatotoxic
CCl effects hepatotoxic
4 CCl effects hepatotoxic
CHCl CCl effects hepatotoxic
3 CHCl CCl effects hepatotoxic
galactosamine CCl effects hepatotoxic
adriamycin administration effect cardiotoxic
galactosamine hepatotoxicity
streptomycin edaravone effect vestibulotoxicity
streptomycin induced vestibulotoxicity
streptomycin induced vestibulotoxicity
indomethacin misoprostol effect induced dysfunction renal
indomethacin misoprostol effect induced dysfunction
indomethacin dysfunction renal
indomethacin dysfunction
cyclosporine nephrotoxicity
cyclosporine role role combination chemotherapeutics development toxicity renal
cyclosporine role role combination chemotherapeutics development toxicity
CSA cyclosporine role role combination chemotherapeutics development toxicity renal
CSA cyclosporine role role combination chemotherapeutics development toxicity
CSA administration potential nephrotoxic
CSA toxicity aggravate administration potential nephrotoxic
CSA increased nephrotoxicity
CSA induced nephrotoxicity
levodopa Tiapride movements involuntary
levodopa Tiapride movements
levodopa Tiapride induced movements involuntary
levodopa Tiapride induced movements
levodopa dyskinesias
Aspirin induces anomalies developmental
Aspirin induces anomalies
acetylsalicylic -RSB- Aspirin induces anomalies developmental
acetylsalicylic -RSB- Aspirin induces anomalies
acid -RSB- Aspirin induces anomalies developmental
acid -RSB- Aspirin induces anomalies
ASA -RSB- Aspirin induces anomalies developmental
ASA -RSB- Aspirin induces anomalies
ASA administered strains Dawley Sprague results compare test confounds detection malformations
ASA malformations
ASA induces focused suggested induce defects ventricular
ASA induces focused suggested induce defects septal
ASA induces focused suggested induce defects
ASA induces focused suggested induce defects VSDs
ASA induces focused suggested induce defects VSDs
ASA induces focused suggested induce defects defects rats hernia diaphragmatic
ASA induces focused suggested induce defects defects rats hernia
ASA induces focused suggested induce defects defects rats DH
ASA induces focused malformations
ASA induces low malformations
ASA administered similar Variations malformations
ASA induced titrating dose achieve dose malformations
haloperidol doses higher incidence parkinsonism
dexmedetomidine sedation associated incidence bradycardia
sulindac group experienced loss hearing
sulindac group experienced loss
oral contraceptives women liver hyperplasia focal
oral contraceptives women liver hyperplasia nodular
oral contraceptives women liver hyperplasia
contraceptives women liver hyperplasia focal
contraceptives women liver hyperplasia nodular
contraceptives women liver hyperplasia
oral contraceptives women liver hyperplasia adenomas
contraceptives women liver hyperplasia adenomas
oral contraceptives use associated hyperplasia focal
oral contraceptives use associated hyperplasia nodular
oral contraceptives use associated hyperplasia
contraceptives use associated hyperplasia focal
contraceptives use associated hyperplasia nodular
contraceptives use associated hyperplasia
oral contraceptives use associated hyperplasia one adenoma
contraceptives use associated hyperplasia one adenoma
suprofen epidemiology syndrome flank
suprofen epidemiology syndrome pain
CGS agonist manner induced responses cataleptic
21680 CGS agonist manner induced responses cataleptic
reserpine induced induced catalepsy
haloperidol induced catalepsy
methamphetamine associated gene psychosis
methamphetamine psychosis
METH methamphetamine psychosis
METH gene 5 induced psychosis
METH patients psychosis
METH associated rs RESULTS patients psychosis
METH HTR association psychosis
METH pathophysiology play HTR CONCLUSION psychosis
ketamine induced tachycardia
sulpiride induced catalepsy
fluphenazine sulpiride induced catalepsy
SCH 23390 fluphenazine sulpiride induced catalepsy
23390 fluphenazine sulpiride induced catalepsy
sulpiride Combination induce potentiation catalepsy
SCH Combination induce potentiation catalepsy
23390 SCH Combination induce potentiation catalepsy
sulpiride fluphenazine induced catalepsy
fluphenazine induced catalepsy
SCH fluphenazine induced catalepsy
23390 SCH fluphenazine induced catalepsy
tacrolimus induced hypertrophy myocardial
tacrolimus induced hypertrophy
tacrolimus induced Herein describe myocardial
tacrolimus induced hypertrophy
tacrolimus concentration reducing resolved hypertrophy Myocardial
tacrolimus concentration reducing resolved hypertrophy
tacrolimus induces hypertrophy myocardial
tacrolimus induces hypertrophy
dobutamine glucagon induced ischemia myocardial
dobutamine glucagon induced ischemia
dobutamine testing attenuates evidence ischemia myocardial
dobutamine testing attenuates evidence ischemia
gold caused anemia aplastic
gold caused anemia
D case caused anemia aplastic
D case caused anemia
penicillamine anemia aplastic
penicillamine anemia
mepivacaine seen addition damage muscle
mepivacaine seen addition damage
lidocaine mepivacaine seen addition damage muscle
lidocaine mepivacaine seen addition damage
dipyridamole hyperemia
dipyridamole resulted stenosis hyperemia
dipyridamole analyzed demonstrated Thallium induced hyperemia
aspirin users users higher risk Thrombotic
aspirin nonusers higher risk Thrombotic
bromocriptine induced psychosis
bromocriptine received seen psychosis
Bromocriptine associated psychosis
bromocriptine cause psychosis
nitric oxide levels gene headache
oxide levels gene headache
nitric oxide induced headache
oxide induced headache
NO oxide induced headache
glyceryl trinitrate induced headache
trinitrate induced headache
GTN trinitrate induced headache
NO donor glyceryl trinitrate induced headache
GTN headache
GTN day developed headache
GTN day developed pronounced headache
NO headache
Levodopa induced dystonia
sodium Contribution valproate syndrome
sodium Contribution valproate syndrome secretion of
sodium Contribution valproate syndrome secretion inappropriate
sodium Contribution valproate syndrome secretion
sodium Contribution valproate syndrome secretion hormone of
sodium Contribution valproate syndrome secretion hormone antidiuretic
sodium Contribution valproate syndrome secretion hormone
valproate syndrome
valproate syndrome secretion of
valproate syndrome secretion inappropriate
valproate syndrome secretion
valproate syndrome secretion hormone of
valproate syndrome secretion hormone antidiuretic
valproate syndrome secretion hormone
sodium valproate administered developed syndrome
sodium valproate administered developed syndrome secretion of
sodium valproate administered developed syndrome secretion inappropriate
sodium valproate administered developed syndrome secretion
sodium valproate administered developed syndrome secretion hormone of
sodium valproate administered developed syndrome secretion hormone antidiuretic
sodium valproate administered developed syndrome secretion hormone
valproate administered developed syndrome
valproate administered developed syndrome secretion of
valproate administered developed syndrome secretion inappropriate
valproate administered developed syndrome secretion
valproate administered developed syndrome secretion hormone of
valproate administered developed syndrome secretion hormone antidiuretic
valproate administered developed syndrome secretion hormone
sodium valproate administered developed syndrome secretion hormone SIADH
valproate administered developed syndrome secretion hormone SIADH
VPA valproate administered developed syndrome
VPA valproate administered developed syndrome secretion of
VPA valproate administered developed syndrome secretion inappropriate
VPA valproate administered developed syndrome secretion
VPA valproate administered developed syndrome secretion hormone of
VPA valproate administered developed syndrome secretion hormone antidiuretic
VPA valproate administered developed syndrome secretion hormone
VPA valproate administered developed syndrome secretion hormone SIADH
VPA administration consider episode SIADH
furosemide pretreated function Renal
furosemide pretreated function
furosemide pretreated function deteriorated significantly
furosemide pretreated function deteriorated
cocaine Stroke
amphetamine cocaine Stroke
cocaine use stroke
amphetamine cocaine use stroke
cocaine stroke
amphetamine cocaine stroke
cocaine 8 using admitted women matched ratio stroke
amphetamine / cocaine 8 using admitted women matched ratio stroke
cocaine use factor stroke
amphetamine cocaine use factor stroke
pyrazinamide induced dysosmia
pyrazinamide related disorder olfactory
pyrazinamide related disorder
pyrazinamide withdrawal disappeared Dysosmia
lovastatin dose associated rare Myopathy
levodopa exhibit primed induced dyskinesias
levodopa exhibit primed induced evaluate locomotor effects dyskinetic
levodopa induced MPTP alleviating efficacious induced dyskinesias
levodopa reproduce likely efficacious induced dyskinesias
levodopa challenge 171555 86929 efficacious induced dyskinesias
MPTP induced parkinsonism
capsaicin elicited pain
capsaicin amount administered evoke sensation painful
fluoxetine prenatally increases prevalence syndrome pulmonary
fluoxetine prenatally increases prevalence syndrome hypertension
fluoxetine prenatally increases prevalence syndrome
fluoxetine effect pulmonary
fluoxetine effect hypertension
fluoxetine exposure induces hypertension pulmonary
fluoxetine exposure induces hypertension
ketoprofen administration decreased aggregation platelet
ketoprofen administration decreased aggregation
ketoprofen group patient developed hematoma
risperidone syndrome Neuroleptic
risperidone syndrome malignant
risperidone syndrome
risperidone developed syndrome neuroleptic
risperidone developed syndrome malignant
risperidone developed syndrome
risperidone observed effects protection ensure syndrome neuroleptic
risperidone observed effects protection ensure syndrome malignant
risperidone observed effects protection ensure syndrome
Quinidine phenylethylbarbiturate induced hepatitis
phenylethylbarbiturate induced hepatitis
quinidine phenylethylbarbiturate administration year patient affected hepatitis
phenylethylbarbiturate administration year patient affected hepatitis
phenylethylbarbiturate itself responsible hepatitis
cytosine treatment neuropathy Peripheral
cytosine treatment neuropathy
arabinoside treatment neuropathy Peripheral
arabinoside treatment neuropathy
cytosine arabinoside therapy play unclear mechanisms neuropathy peripheral
cytosine arabinoside therapy play unclear mechanisms neuropathy
arabinoside therapy play unclear mechanisms neuropathy peripheral
arabinoside therapy play unclear mechanisms neuropathy
Sorafenib induced due spasm coronary
Sorafenib induced due spasm artery
Sorafenib induced due spasm
sorafenib induced spasm coronary
sorafenib induced spasm artery
sorafenib induced spasm
acetaminophen overdose failure associated edema cerebral
acetaminophen overdose failure associated edema
acetaminophen overdose failure hepatic
acetaminophen overdose failure
acetaminophen patient present induced unresponsive failure signs edema cerebral
acetaminophen patient present induced unresponsive failure signs edema
acetaminophen patient present induced unresponsive failure fulminant
acetaminophen patient present induced unresponsive failure hepatic
acetaminophen patient present induced unresponsive failure
D treated cirrhosis case polymyositis
penicillamine case polymyositis
D complications one develop Polymyositis
penicillamine Polymyositis
D receiving developed polymyositis
penicillamine therapy D receiving developed polymyositis
D followed polymyositis
penicillamine therapy followed polymyositis
salbutamol triggered tachyarrhythmia atrial
salbutamol triggered tachyarrhythmia
Salbutamol presented trigger SIAT
alcohol impairment growth
alcohol impairment
alcohol recognition resulted growth reduced
alcohol recognition resulted growth cerebellar
alcohol recognition resulted growth
alcohol recognition resulted growth cranial decreased
alcohol recognition resulted growth cranial
alcohol recognition resulted growth cranial growth to
alcohol recognition resulted growth cranial growth body
alcohol recognition resulted growth cranial growth
imipenem cilastatin doses receiving developed seizures
/ cilastatin doses receiving developed seizures
cilastatin doses receiving developed seizures
oral contraceptives associated factors pathogenesis tumors liver
oral contraceptives associated factors pathogenesis tumors
contraceptives associated factors pathogenesis tumors liver
contraceptives associated factors pathogenesis tumors
oral steroids using seen tumors liver
oral steroids using seen tumors
contraceptive steroids using seen tumors liver
contraceptive steroids using seen tumors
Oral Contraceptives Associated Liver
Oral Contraceptives Associated Tumors
Contraceptives Associated Liver
Contraceptives Associated Tumors
digoxin administration assessment dysfunction sexual
digoxin administration assessment dysfunction
lithium therapy secondary block atrioventricular
lithium therapy secondary block
lithium effects reported dysfunction Sinus
lithium effects reported dysfunction node
lithium effects reported dysfunction
lithium therapy secondary developed attacks block atrioventricular
lithium therapy secondary developed attacks block atrioventricular AV
lithium therapy secondary developed attacks block
vancomycin aminoglycoside receiving patients confined occurred Thrombophlebitis
vancomycin aminoglycoside receiving patients confined nephrotoxicity ototoxicity
6 caused disease veno Hepatic
6 caused disease veno
6 caused disease occlusive
6 caused disease
thioguanine veno Hepatic
thioguanine veno
thioguanine veno disease occlusive
thioguanine veno disease
6 man year developed liver disease veno
6 man year developed liver disease occlusive
6 man year developed liver disease
6 man year developed liver of
6 man year developed liver the
6 man year developed liver
thioguanine year developed liver disease veno
thioguanine year developed liver disease occlusive
thioguanine year developed liver disease
thioguanine year developed liver of
thioguanine year developed liver the
thioguanine year developed liver
6 related occlusive case presented observe features veno hepatic
6 related occlusive case presented observe features veno
6 related occlusive case presented observe features veno disease occlusive
6 related occlusive case presented observe features veno disease
thioguanine case presented observe features veno hepatic
thioguanine case presented observe features veno
thioguanine case presented observe features veno disease occlusive
thioguanine case presented observe features veno disease
Heparin induced thrombocytopenia
Heparin thrombocytopenia
Heparin thrombocytopenia HIT
heparin reaction Heparin thrombocytopenia
heparin reaction Heparin thrombocytopenia HIT
heparin transplantation HIT
heparin antibody antibody HIT
UFH developed related HIT
dobutamine related myocarditis
dobutamine related myocarditis hypersensitivity
dobutamine related myocarditis eosinophilic
Succinylcholine induced rigidity masseter
Succinylcholine induced rigidity muscle
Succinylcholine induced rigidity
succinylcholine administration describe case rigidity masseter
succinylcholine administration describe case rigidity muscle
succinylcholine administration describe case rigidity
succinylcholine administration describe case rigidity jaw
succinylcholine administration describe case rigidity jaw steel of
succinylcholine administration describe case rigidity jaw steel
Sch administration describe case rigidity masseter
Sch administration describe case rigidity muscle
Sch administration describe case rigidity
Sch administration describe case rigidity jaw
Sch administration describe case rigidity jaw steel of
Sch administration describe case rigidity jaw steel
butylated hydroxyanisole induced rats carcinogenesis forestomach
butylated hydroxyanisole induced rats carcinogenesis
hydroxyanisole induced rats carcinogenesis forestomach
hydroxyanisole induced rats carcinogenesis
butylated hydroxyanisole tumorigenesis forestomach
butylated hydroxyanisole tumorigenesis
hydroxyanisole tumorigenesis forestomach
hydroxyanisole tumorigenesis
BHA hydroxyanisole tumorigenesis forestomach
BHA hydroxyanisole tumorigenesis
BHA given groups increased incidence tumors forestomach
BHA given groups increased incidence tumors
BHA carcinogen forestomach
BHA carcinogen forestomach carcinogenesis
cocaine marker oscillation pupillary
cocaine marker oscillation
cocaine marker oscillation measure paranoia
Cocaine induced remains paranoia
Cocaine induced remains paranoia CIP
Cocaine induced remains drug model paranoia
amiodarone administration pain low
amiodarone administration pain back
amiodarone administration pain
amiodarone loading initiation experienced pain low
amiodarone loading initiation experienced pain back
amiodarone loading initiation experienced pain
aspirin ingestion salicylates association lack disappearing syndrome Reye
aspirin ingestion salicylates association lack disappearing syndrome
Penicillamine induced glomerulonephritis
D months presented rapidly glomerulonephritis
penicillamine treatment woman arthritis presented rapidly glomerulonephritis
D months presented rapidly glomerulonephritis RPGN
penicillamine treatment woman arthritis presented rapidly glomerulonephritis RPGN
D course case RPGN
penicillamine treatment emphasizes case RPGN
nitroglycerin caused impairment hypotension
nitroglycerin caused impairment memory
nitroglycerin caused impairment
nitroglycerin onset administered tested preserve hypotension
NTG nitroglycerin onset administered tested preserve hypotension
NTG NIMO saline injected those showed Mice subjected hypotensive
NTG delayed injected those showed Mice subjected hypotensive
NTG injection produced impairment memory mice had hypotension
NTG caused improve absence hypotension
isoniazid pretreated induced bradycardia
isoniazid hypotension doses induced tachycardia bradycardia
isoniazid hypotension
isoniazid bradycardia
Isoniazid increased bradycardia
Ammonia higher patients complained drowsiness
NH 3 Ammonia higher patients complained drowsiness
3 Ammonia higher patients complained drowsiness
VPA levels similar higher patients complained drowsiness
puromycin amino injection induced NS
amino injection induced NS
nucleoside amino injection induced NS
PAN amino injection induced NS
PAN injection observed established NS
PAN induced NS
Doxorubicin cardiomyopathy
doxorubicin bed experienced cardiomyopathy
doxorubicin interaction fact attributed cardiomyopathy
lithium therapy years hypothyroidism
lithium therapy onset years hypothyroidism
lithium therapy factor hypothyroidism
Doxorubicin cardiomyopathy
DOX cardiomyopathy
DOX cardiomyopathy development elucidate studied B induced cardiomyopathy
DOX induction investigating mice B studied elucidate development cardiomyopathy
DOX induction investigating mice B induced cardiomyopathy
DOX cardiomyopathy
DOX treatment antagonists utilizing cardiomyopathy
paroxetine fluoxetine receiving women sexually
paroxetine fluoxetine receiving women dysfunctional
sertraline fluoxetine receiving women sexually
sertraline fluoxetine receiving women dysfunctional
fluoxetine receiving women sexually
fluoxetine receiving women dysfunctional
Pilocarpine age impairment
Pilocarpine age impairment discrimination in
Pilocarpine age impairment discrimination auditory
Pilocarpine age impairment discrimination location
Pilocarpine age impairment discrimination
Pilocarpine induced epilepticus status
Pilocarpine induced epilepticus
Pilocarpine induced resulted epilepticus status
Pilocarpine induced resulted epilepticus
muscimol drugs jerks myoclonic
muscimol drugs jerks
muscimol produced jerks myoclonic
muscimol produced jerks
muscimol myoclonus
muscimol myoclonus management beneficial found seems myoclonus
phenytoin administration developed bradycardia
fat diet sensitive rats obese
fat diet induces obesity
doxorubicin dose administered day regimen led cardiotoxicity dysfunction cardiac
doxorubicin dose administered day regimen led cardiotoxicity dysfunction
risperidone hyperprolactinemia
risperidone treated % present Hyperprolactinemia
risperidone started occurred occurred hyperprolactinemia
risperidone link study induced treatment hyperprolactinemia
ketamine buffers decreases duration hallucinations
haloperidol potentiation induced catalepsy
apomorphine prevention catalepsy induced potentiation induced hyperactivity
pilocarpine acid seizures
kainic pilocarpine acid seizures
acid seizures
pilocarpine acid seizures epilepticus status
pilocarpine acid seizures epilepticus
kainic pilocarpine acid seizures epilepticus status
kainic pilocarpine acid seizures epilepticus
acid seizures epilepticus status
acid seizures epilepticus
pilocarpine activity evaluated beta metabolites seizures
kainic acid beta metabolites seizures
acid beta metabolites seizures
pilocarpine protecting effective Steroids induced seizures
pilocarpine protecting effective Steroids induced seizures epilepticus status
pilocarpine protecting effective Steroids induced seizures epilepticus
pilocarpine seizures
pilocarpine seizures protecting potent had values TD divided protection seizure
kainic acid induced seizures
acid induced seizures
kainic acid induced seizures onset produced protect seizures
acid induced seizures onset produced protect seizures
kainic acid administered However obtained seizures
acid administered However obtained seizures
kainic acid administered However obtained seizures epilepticus status
kainic acid administered However obtained seizures epilepticus
acid administered However obtained seizures epilepticus status
acid administered However obtained seizures epilepticus
pilocarpine acid seizures
kainic pilocarpine acid seizures
acid seizures
pilocarpine acid seizures epilepticus status
pilocarpine acid seizures epilepticus
pilocarpine acid protecting effective utility treatment forms epilepticus status
pilocarpine acid protecting effective utility treatment forms epilepticus
kainic pilocarpine acid seizures epilepticus status
kainic pilocarpine acid seizures epilepticus
acid seizures epilepticus status
acid seizures epilepticus
kainic pilocarpine acid protecting effective utility treatment forms epilepticus status
kainic pilocarpine acid protecting effective utility treatment forms epilepticus
acid protecting effective utility treatment forms epilepticus status
acid protecting effective utility treatment forms epilepticus
oxacillin associated vasculitis Cutaneous
oxacillin associated vasculitis leucocytoclastic
oxacillin associated vasculitis
oxacillin treated man year developed failure renal
oxacillin treated man year developed failure
Oxacillin included drugs cause vasculitis leucocytoclastic
Oxacillin included drugs cause vasculitis
DX treated those treated animals appeared proteinuria
doxorubicin treatment prolonged intense 2 appeared Proteinuria
DX DXNP difference 2 appeared Proteinuria
morphine analgesia hypothermia
morphine analgesia catalepsy
morphine bradycardia
morphine induced bradycardia
morphine bradycardia induced hypotension
morphine induced hypotension
methylprednisolone Hypotension
methylprednisolone Hypotension bradycardia
methylprednisolone Hypotension asystole
methylprednisolone year administration hypotension
methylprednisolone year administration hypotension bradycardia
methylprednisolone year administration hypotension asystole
amiodarone Hepatotoxicity
amiodarone treatment due hepatitis presented given review hepatotoxicity
amiodarone hepatotoxicity
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis cirrhosis
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis liver of
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis liver the
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis liver
amiodarone treatment due injury steatosis
amiodarone treatment due injury hepatic
amiodarone treatment due injury
levodopa involved unclear dyskinesia
3 induced anaemia
azido 3 induced anaemia
3 dideoxythymidine understood induced anaemia
' 3 dideoxythymidine understood induced anaemia
dideoxythymidine understood induced anaemia
AZT dideoxythymidine understood induced anaemia
AZT anaemia
AZT produced anaemia
AZT treated increased number fold anaemia
AZT treated appropriate observed degree anaemia
AZT treated degrees anaemia
AZT observed anaemia
AZT induced anaemia
amisulpride mg doses man hypertension
tiapride mg mg doses man headache vomiting
tiapride mg mg doses man headache
amisulpride mg doses man headache
tiapride mg mg doses man hypertension
amisulpride mg doses man headache vomiting
amisulpride therapy crisis hypertensive
tiapride amisulpride therapy crisis hypertensive
amisulpride crisis hypertensive
tiapride amisulpride crisis hypertensive
melatonin effects narcosis
Melatonin affects clear influence drug narcosis
Melatonin pre affected narcosis
melatonin dose caused produced reduction duration narcosis
ketamine narcosis
diazepam ketamine narcosis
Melatonin 0 5 kg influenced duration latency narcosis
melatonin narcosis
AZT induced cardiomyopathy
zidovudine investigate triggers Fas pathway model DCM
3 azido zidovudine investigate triggers Fas pathway model DCM
' 3 azido zidovudine investigate triggers Fas pathway model DCM
- azido zidovudine investigate triggers Fas pathway model DCM
azido zidovudine investigate triggers Fas pathway model DCM
2 azido zidovudine investigate triggers Fas pathway model DCM
3 triggers Fas pathway model DCM
deoxythymidine 3 triggers Fas pathway model DCM
AZT 3 triggers Fas pathway model DCM
AZT concentrations containing libitum received triggers Fas pathway model DCM
AZT - treated developed dilation cardiac
AZT - treated developed dilation
ribavirin treatment b case parasitosis delusional
ribavirin treatment b case parasitosis
pegylated alpha patient parasitosis delusional
pegylated alpha patient parasitosis
interferon alpha patient parasitosis delusional
interferon alpha patient parasitosis
alpha patient parasitosis delusional
alpha patient parasitosis
2 b case parasitosis delusional
2 b case parasitosis
b case parasitosis delusional
b case parasitosis
ribavirin b year woman developed parasitosis delusional
ribavirin b year woman developed parasitosis
pegylated alpha developed parasitosis delusional
pegylated alpha developed parasitosis
interferon alpha developed parasitosis delusional
interferon alpha developed parasitosis
alpha developed parasitosis delusional
alpha developed parasitosis
2 b year woman developed parasitosis delusional
2 b year woman developed parasitosis
b year woman developed parasitosis delusional
b year woman developed parasitosis
MPTP rendered parkinsonian
MDMA users observed evidence impairment memory
MDMA users observed evidence impairment
MDMA use associated functioning impaired
MDMA use associated functioning memory
MDMA use associated functioning
MDMA use associated lead impairments memory
MDMA use associated lead impairments
MDMA use use lead associated functioning impaired
MDMA use use lead associated functioning memory
MDMA use use lead associated functioning
MDMA use use lead impairments memory
MDMA use use lead impairments
lidocaine group % fatal fatal dose convulsions
lidocaine group % fatal fatal % bupivacaine induced seizures
chloroprocaine group % induced bupivacaine % fatal dose convulsions
chloroprocaine group % induced seizures
bupivacaine % fatal dose convulsions
bupivacaine induced seizures
testosterone implanted rats developed incidence cancer prostate
testosterone implanted rats developed incidence cancer
testosterone developed cancer prostate
testosterone developed cancer
testosterone prostatitis
5 presented pain chest
5 presented pain
fluorouracil administration metastasis presented pain chest
fluorouracil administration metastasis presented pain
5 administration metastasis presented pain chest
5 administration metastasis presented pain
FU 5 administration metastasis presented pain chest
FU 5 administration metastasis presented pain
paroxetine related syndrome neuroleptic
paroxetine related syndrome malignant
paroxetine related syndrome
alprazolam paroxetine related syndrome neuroleptic
alprazolam paroxetine related syndrome malignant
alprazolam paroxetine related syndrome
paroxetine occur presented symptoms syndrome malignant neuroleptic
paroxetine occur presented symptoms syndrome malignant
paroxetine occur presented symptoms syndrome
paroxetine occur presented symptoms syndrome NMS
paroxetine occur presented demonstrating NMS
alprazolam treatment paroxetine occur presented symptoms syndrome malignant neuroleptic
alprazolam treatment paroxetine occur presented symptoms syndrome malignant
alprazolam treatment paroxetine occur presented symptoms syndrome
alprazolam treatment paroxetine occur presented symptoms syndrome NMS
alprazolam treatment paroxetine occur presented demonstrating NMS
Quinidine hepatitis
quinidine had hepatotoxicity
penicillamine therapy complications recorded rashes polymyositis
penicillamine therapy complications recorded rashes erythematosus systemic
penicillamine therapy complications recorded rashes erythematosus lupus
penicillamine therapy complications recorded rashes erythematosus
penicillamine therapy complications recorded rashes Skin
penicillamine therapy complications recorded rashes
penicillamine therapy complications recorded rashes gravis myasthenia
penicillamine therapy complications recorded rashes gravis
penicillamine therapy complications recorded rashes proteinuria
chloramphenicol administration anemia aplastic
chloramphenicol administration anemia
chloramphenicol beginning undergoing died anemia aplastic
chloramphenicol beginning undergoing died anemia
chloramphenicol associated pattern anemia aplastic
chloramphenicol associated pattern anemia
chloramphenicol treatment report anemia aplastic
chloramphenicol treatment report anemia
ifosfamide Hallucinations
ifosfamide effect Hallucinations
ifosfamide cases reported hallucinations
ifosfamide interviewed authors METHODS hallucinations
ifosfamide hallucinations
picrotoxin pentetrazol induced convulsions inhibitors effects induction seizure
picrotoxin pentetrazol induced convulsions
flurothyl pentetrazol induced convulsions inhibitors effects induction seizure
flurothyl pentetrazol induced convulsions
pentetrazol induced convulsions inhibitors effects induction seizure
pentetrazol induced convulsions
PTZ prostaglandins induction seizure
PTZ prostaglandins induction effects inhibitors convulsions
bicuculline electroshock evaluated investigate relationship prostaglandins induction seizure
bicuculline electroshock evaluated investigate relationship prostaglandins induction effects inhibitors convulsions
picrotoxin convulsions fluorthyl induced convulsions
picrotoxin convulsions
fluorthyl induced convulsions
fluorthyl convulsions
PTZ fluorthyl induced convulsions
PTZ fluorthyl convulsions
bicuculline picrotoxin convulsions fluorthyl induced convulsions
bicuculline picrotoxin convulsions
azidothymidine induced suppression marrow
azidothymidine induced suppression
AZT induced anemia leukopenia
AZT induced anemia
AZT administration rendered anemic leukopenic
AZT administration rendered reversed induced anemia leukopenia
AZT administration water drinking days reversed rendered anemic leukopenic
AZT administration water drinking days reversed induced anemia leukopenia
AZT induced reversed rendered anemic leukopenic
AZT induced anemia leukopenia
AZT administration rendered anemic
AZT administration rendered reversed induced anemia
AZT administration water drinking days reversed rendered anemic
AZT administration water drinking days reversed induced anemia
AZT induced reversed rendered anemic
AZT induced anemia
AZT coadministered reduced AZT induced toxicity marrow
AZT coadministered reduced AZT induced toxicity
AZT induced toxicity marrow
AZT induced toxicity
levodopa overflow dyskinesias
levodopa therapy complications assessed dyskinesias
levodopa therapy complications assessed dyskinesias LID
levodopa complications assessed dyskinesias
levodopa complications assessed dyskinesias LID
levodopa with LID
levodopa dyskinesias
levodopa dyskinesias disease LID
levodopa assessed lift score dyskinesia
levodopa increased LID
isoproterenol status mangiferin Role infarction myocardial
isoproterenol status mangiferin Role infarction
isoproterenol Anacardiaceae induced infarction myocardial
isoproterenol Anacardiaceae induced infarction
isoproterenol Anacardiaceae induced infarction MI
ISPH Anacardiaceae induced infarction myocardial
ISPH Anacardiaceae induced infarction
ISPH Anacardiaceae induced infarction MI
ISPH induced rats MI
ISPH exerts due MI
quipazine aggressiveness induced deprivation induced twitches head
quipazine aggressiveness induced deprivation induced twitches
apomorphine deprivation induced aggressiveness
quipazine increased reduced twitches head
quipazine increased reduced twitches
apomorphine increased induced aggressiveness
oestrogen Long increased risk disease embolism stroke
oestrogen Long increased risk disease embolism gallbladder
oestrogen Long increased risk disease
oestrogen Long increased risk thrombo venous
oestrogen Long increased risk thrombo
oestrogen Long increased risk disease embolism
ketamine catatonia
ketamine idolamines catatonia
ketamine increased duration catatonia
dopamine pretreatment increased duration catatonia
ketamine catatonia
dopamine appeared act induction catatonia
adriamycin dose developed failure congestive
adriamycin dose developed failure heart
adriamycin dose developed failure
adriamycin 2 mg receiving developed leukemia myeloblastic acute
adriamycin 2 mg receiving developed leukemia myeloblastic
adriamycin 2 mg receiving developed leukemia
Amphetamine similar locomotor
Amphetamine similar hyperactivity
Cyclophosphamide cancer bladder
Cyclophosphamide cancer
cyclophosphamide associated cancer bladder
cyclophosphamide associated cancer
Cyclophosphamide associated disease tumor bladder
Cyclophosphamide associated disease tumor
Amisulpride tic
Amisulpride symptoms like
Amisulpride symptoms
amisulpride dose reduced resolved symptoms tic
amisulpride dose reduced resolved symptoms like
amisulpride dose reduced resolved symptoms
amisulpride quetiapine occur suggests tic
amisulpride quetiapine occur symptoms like
amisulpride quetiapine occur symptoms
carrageenan model writhing
carrageenan model writhing induced acid paw model edema
